Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 18, 2026.

Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets

Beatriz Ballester, Javier Milara, Julio Cortijo

International Journal of Molecular Sciences · 2019 · Review · CC BY

doi:10.3390/ijms20030593

Abstract

Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pulmonary disease with a median survival of 2–4 years after diagnosis. A significant number of IPF patients have risk factors, such as a history of smoking or concomitant emphysema, both of which can predispose the patient to lung cancer (LC) (mostly non-small cell lung cancer (NSCLC)). In fact, IPF itself increases the risk of LC development by 7% to 20%. In this regard, there are multiple common genetic, molecular, and cellular processes that connect lung fibrosis with LC, such as myofibroblast/mesenchymal transition, myofibroblast activation and uncontrolled proliferation, endoplasmic reticulum stress, alterations of growth factors expression, oxidative stress, and large genetic and epigenetic variations that can predispose the patient to develop IPF and LC. The current approved IPF therapies, pirfenidone and nintedanib, are also active in LC. In fact, nintedanib is approved as a second line treatment in NSCLC, and pirfenidone has shown anti-neoplastic effects in preclinical studies. In this review, we focus on the current knowledge on the mechanisms implicated in the development of LC in patients with IPF as well as in current IPF and LC-IPF candidate therapies based on novel molecular advances.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 18, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

Idiopathic pulmonary fibrosis (IPF) is a form of chronic, progressive fibrosing interstitial pneumonia of unknown cause that occurs primarily in older adults. IPF is associated with the histopathologic and/or radiologic pattern of usual interstitial pneumonia (UIP) that is limited to the lungs. The disease course of IPF is variable and somewhat unpredictable, nevertheless, progression to end-stage respiratory insufficiency and death after the onset of symptoms from diagnosis is 2–4 years. Pulmonary and extrapulmonary comorbid conditions, such as lung cancer (LC), are commonly associated to IPF, altering the disease course and mortality. Links between pulmonary fibrosis and LC have been suggested as early as 1965 and are based on the multiple common genetic, molecular, and cellular processes that connect both diseases and can predispose the patient to develop IPF and LC.

On its own, pulmonary fibrosis is a risk factor for developing lung carcinogenesis. Moreover, elder age, male sex, history of smoking, and coexisting emphysema are also strong risk factors that contribute to developing LC in IPF patients. The prevalence of LC in IPF patients ranges from 2.7% to 48% (Table 1) and is significantly higher than in the general population. Otherwise, the incidence of LC in IPF patients is reported to be 11.2–36 cases per 1,000 persons per year, which increases with each year following IPF diagnosis. Moreover, IPF patients that are diagnosed with LC have a reduced mean survival time (1.6–1.7 years), compared to IPF patients without LC diagnosis and Kato et al. reported 53.5%, 78.6%, and 92.9% as 1-, 3-, and 5-year all-cause mortality rates after LC diagnosis in IPF patients.

2. Histological Subtypes and Parenchymal Distribution of Lung Cancer in Idiopathic Pulmonary Fibrosis

In the general population, the predominant type of LC is non-small cell lung cancer (NSCLC). Likewise, NSCLC is the predominant type of LC in LC-IPF patients. Furthermore, adenocarcinoma (ADC) is the most common subtype of histological NSCLC in the general population. However, the most frequent histological subtype of LC in IPF has been controversial over the past few years (Table 2). Recently, the majority of studies have shown that squamous cell carcinoma (SQC) is the most frequent type of LC in IPF patients, while ADC is the second most frequent. Moreover, some isolated cases of large cell carcinoma and small cell lung cancer (SCLC) have also been reported.

Similarly to fibrotic lesions, lung carcinomas are generally more frequently found in the peripheral area of the lungs in IPF patients, i.e., in the lower lobes, and are associated with honeycomb lesions, developing from honeycomb areas or in the border between honeycombing and non-fibrotic areas, and epithelial metaplasia. In general, squamous metaplasia, but not cuboidal cell metaplasia or bronchial cell metaplasia, have been observed more frequently in LC-IPF patients than in IPF patients without lung carcinoma. Then, it is speculated that it might reflect a constitutional susceptibility of IPF patients of developing lung carcinoma.

3.1. Cell Transformations in the Mesenchymal Phenotype

IPF is characterised by an excess of myofibroblasts that are persistently activated in fibrotic lungs. The activated myofibroblasts are stellate- or spindle-shaped, and are characterised by the secretion of extracellular matrix (ECM) components (a characteristic shared with fibroblasts), such as collagen type I, and by the formation of contractile apparatus (a characteristic shared with airway smooth muscle cells), such as α-smooth muscle actin (α-SMA) microfilaments. In IPF lungs, myofibroblasts have heterogeneous phenotypes (Figure 1). The classic concept is that tissue injury induces the activation of resident fibroblasts to proliferate and express constituents of the ECM and α-SMA fibres. One contemporary theory is that tissue injury in the presence of transforming growth factor (TGF-β) induces epithelial to mesenchymal cell transition (EMT). In detail, EMT is part of an unabated form of wound healing in which alveolar type II (ATII) cells can serve as a source for the increased myofibroblast-like pool that eventually leads to organ destruction if the primary inflammatory insult that triggered the wound healing is not removed or attenuated. Another contemporary theory of myofibroblast activation is that circulating fibrocytes that originate from the bone marrow are mesenchymal progenitor cells that home and extravasate into sites of tissue injury, and differentiate into the myofibroblast-like phenotype in response to TGF-β and endothelin 1. Pulmonary arterial endothelial cell to mesenchymal transition (EnMT) has been suggested as another source of myofibroblasts that potentially contribute to lung fibrosis and pulmonary hypertension and is often associated with IPF, which portends a poor prognosis. Finally, there are two emerging theories that consider pleural mesothelial cells or lung pericytes as significant sources of lung myofibroblasts in IPF.

Similarly to IPF, cancer-associated fibroblasts (CAFs) are also important players in LC because they exhibit mesenchymal-like features and have heterogeneous phenotypes (Figure 1). Lung resident fibroblasts surrounding the malignancy are thought to be the first responders to the site of insult that the tumour creates. Resident epithelial cells—generally bronchiolar epithelial cells—can also undergo a partial and possibly reversible EMT during the early steps of carcinogenesis, cancer invasion, and metastasis. Likewise, fibrocytes recruited from the peripheral circulation have also been suggested as a potential source of CAFs. It has also been observed that up to 40% of CAFs arise as a consequence of EndMT in two different murine cancer models, suggesting that EndMT may play a role in tumour angiogenic sprouting into adjacent tissue. In the tumour environment, vascular pericytes have also been associated with tumour vasculature. Pericytes that detach from the tumour microvasculature have been shown to undergo differentiation into stromal fibroblasts via the action of platelet-derived growth factor-BB (PDGF-BB), which significantly contributes to tumour invasion and metastasis. Finally, pleural mesothelial cells are also hypothesised as a source of CAFs, where a mesothelial precursor lineage has been identified as being capable of clonally generating fibroblasts in the lungs, kidney, liver, and gut. Also, it has been reported that an overexpression of mesothelin in lung ADC is induced by tobacco-related carcinogens.

3.2.1. Apoptosis and Autophagy

Growing evidence indicates a prominent role of enhanced endoplasmic reticulum (ER) stress in IPF, resulting in an unfolded protein response (UPR). This response mechanism activates biochemical pathways to meet the demands of protein folding. However, if that is no longer feasible, a terminal UPR directs alveolar epithelium cells towards apoptosis. By contrast, IPF myofibroblasts and cancer cells escape apoptosis. Regarding the role of ER-stress in tumourigenesis, it is controversial, nevertheless, recent evidence shows that ER stress may attenuate senescence and promote tumorigenesis (Figure 1).

Despite elevated ER stress, there is evidence that autophagy is defective in IPF (Figure 1), which promotes lung fibroblast differentiation into myofibroblasts via excessive ECM production and fibroblast resistance to apoptosis. In LC, autophagy functions as a double-edged sword because it suppresses tumorigenesis in a limited number of contexts while facilitating it in most others. In fact, it has been observed that autophagy can promote or inhibit apoptosis under different cellular contexts within the same tumour cell population. Therefore, therapeutic targeting of autophagy in cancer is sometimes viewed as controversial.

3.2.2. Cellular Proliferation

Evidence strongly supports the persistent activation of proliferative signalling pathways in IPF (Figure 1). In fact, myofibroblasts sustain their own growth through the autocrine production of TGFβ1 and partly lose their ability to produce anti-fibrotic prostaglandin E2 (PGE2). Further, they show a lack of response to the inhibitory activity of PGE2, and to other antiproliferative signals. The receptors for platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and fibroblast growth factor (FGF) have also recently been implicated in the sustained proliferation signalling of pulmonary fibroblasts. However, this persistent activation is not definitively linked with aberrant fibroblast proliferation in vivo and the role of excessive fibroblast proliferation as a pathogenic mechanism of IPF is unclear. By contrast, aberrant proliferation of cancer cells and sustained proliferative signalling has been described as “arguably the most fundamental trait of cancer cells”.

3.2.3. Altered Cell-Cell Communications

Intercellular channels that are formed by connexins are essential for the synchronisation of cell proliferation and tissue repair. In particular, the expression of connexin 43 (Cx43) is considered crucial in fibroblast-to-fibroblast communication. In IPF fibroblasts, Cx43 expression is strongly down-regulated, leading to a loss of proliferative control. Similarly, cancer cell lines from mouse and human lung carcinoma have low levels or an absence of Cx43 expression, which results in reduced cell-to-cell communication (Figure 1); this may explain both the release of cells from contact-inhibition control, and the uncontrolled proliferation that characterises this disease.

3.2.4. Senescence

Analyses of cell types in the lungs of both human IPF and the bleomycin-injured mouse model have demonstrated that fibroblasts and epithelial cells acquire senescent identities. Senescence appears to be a central phenotype that promotes lung fibrosis through increased production of a complex senescence-associated secretory phenotype (SASP) based on growth factors, cytokines, chemokines, and matrix metalloproteinases, as well as acquired apoptosis resistance in IPF fibroblasts (Figure 1). However, therapeutic management of cell senescence is controversial in cancer. On the one hand, cell senescence could limit the replicative capacity of cells and ultimately prevent their proliferation in different stages of malignancy, while providing a protective barrier to neoplastic expansion. On the other hand, it has been proposed that senescent fibroblasts may promote tumour progression, possibly by secreting an SASP based on certain matrix metalloproteases, growth factors, and cytokines.

3.2.5. Tissue Invasion

IPF lung fibroblasts are characterised by their ability to invade through the basement membrane and the ECM via the action of metalloproteinases. This characteristic is also an important hallmark of cancer (Figure 1). Unlike cancers that can disseminate over long distances because they acquire further invasive mechanisms, fibrotic lung fibroblasts are restricted to local invasion. The capacity of cancer cells to infiltrate the surrounding tissue is strictly related to the expression of laminin, heat shock protein 27, and fascin. Interestingly, in IPF, it has been shown that bronchiolar basal cells surrounding the fibroblast foci express large amounts of these proteins, which induce cell motility and invasiveness of myofibroblasts. Therefore, targeting these molecules may be a feasible strategy to restrain myofibroblast tissue invasion in LC-IPF patients.

3.2.6. Inflammation

The role of inflammation in IPF is controversial, although evidence shows the existence of a predominant phenotype of fibrosis-associated macrophages (FAMs) that are alternatively activated. These are an M2 phenotype of FAMs that facilitate the enhanced production of FGFs, profibrotic cytokines, and matrix metalloproteinases. Like FAMs, tumour-associated macrophages also display an M2 phenotype and support tumour growth through their ability to promote angiogenesis, activate mesenchymal cells, remodel the matrix, and suppress effector T-cell responses. Thus, M2 macrophages could be considered key effectors in the development of LC associated with pulmonary fibrosis.

4.1. Growth Factors

TGFβ is a major profibrotic growth factor and is often chronically overexpressed in cancer and fibrosis (Table 3). TGFβ can be activated by αVβ6 integrin and, in IPF, TGFβ1 mediates fibrogenesis by antiproliferative action and apoptosis in alveolar epithelial cells (AECs) or by stimulation of fibroblast differentiation to myofibroblasts, synthesis of ECM proteins, and inhibition of ECM degradation. TGFβ also induces the production of fibrogenic or angiogenic growth factors and is known to strongly elicit EMT and EndMT. In the early stages of cancer pathogenesis, TGFβ acts as a tumour suppressor because it inhibits the growth of many cell types and delays the appearance of primary tumors. However, after the appearance of them, TGFβ promotes tumour progression, because it can induce EMT and EndMT, and suppresses immune surveillance. Therefore, during tumour progression, TGFβ triggers the formation of spontaneous lung metastases. Finally, TGFβ is also central in the development of the tumour stroma because TGFβ1 also activates CAFs.

Tyrosine kinase receptor ligands, such as PDGF, VEGF, and FGF, are aberrantly expressed in LC and IPF (Table 3). In IPF, PDGF plays an important role in inducing the secretion of ECM components and growth factors in fibroblasts. It also promotes fibroblast proliferation and recruits fibrocytes to the lung. Furthermore, TGFβ1, FGF, and tumour necrosis factor-α exhibit PDGF-dependent profibrotic activity. Otherwise, PDGF signalling is also important for tumour growth, angiogenesis, and lymphangiogenesis in cancer. In fact, it has been shown that crenolanib (PDGF receptor inhibitor) is capable of suppressing proliferation and inducing apoptosis in a dose-dependent manner using A549 cells as a NSCLC model system. Moreover, it has been shown that crenolanib-treated A549 cells have reduced migratory activity in response to inducers of chemotaxis, and the antitumor activity of this drug has been confirmed in an NSCLC xenograft tumor model. Finally, it has been observed that PDGF regulates VEGF expression in NSCLC via an autocrine mechanism, and is also involved in the recruitment of CAFs to the tumour mass. The contribution of VEGF to IPF is not fully understood because there is still debate on the role of vascular remodelling in IPF. However, in addition to the role of VEGF in tumour angiogenesis, accumulating evidence suggests that it can act directly on cancer cells to regulate growth, migration, and production of several pro-angiogenic factors. FGF is also released by damaged epithelial cells and activated fibroblasts during the remodelling processes. It was found that FGF signalling is required for fibroblast expansion within fibrotic areas. FGF can also affect the proliferation, treatment sensitivity, and apoptosis of LC cells.

Another important fibrogenic growth factor in LC is connective tissue growth factor (CTGF). In IPF, CTGF induces fibroblast proliferation and ECM deposition. By contrast, it has been observed that CTGF inhibits metastasis and invasion of human lung ADC, and its expression is suppressed in many NSCLCs (Table 3).

Several other growth factors are involved in IPF and LC, but we have not included them in this review because they are not the focus of the new therapies currently being developed.

4.2. Lysophosphatidic Acid (LPA)

LPA, a profibrotic mediator with proinflammatory activity, is released by platelets during epithelial injury. Extracellular production of LPA is catalysed by autotaxin (ATX) and further regulated by phospholipid phosphatases (PLPP). IPF patients have increased LPA levels in their bronchoalveolar lavage fluid (BALF) (Table 3), and recently, it has been shown that LPA signalling mediates both the fibroblast recruitment and vascular leakage induced by lung injury in a bleomycin model of pulmonary fibrosis. Moreover, it has recently been shown that the ATX/PLPP3-LPA/LPA receptor 1 (LPAR1) axis has a procarcinogenic role in lung carcinogenesis.

4.3. Cytokines and Chemokines

Epithelial injury causes an imbalance in T-helper type 1 (Th1)/type 2 (Th2) cytokine expression, which results in a stronger Th2 response. In particular, there is evidence that interleukin 13 (IL-13) plays a dominant role in the pathogenesis of fibrosis in the lungs of IPF patients (Table 3). IL-13 triggers the transformation of fibroblasts to myofibroblasts via the TGFβ-dependent and -independent pathways, while also inducing epithelial apoptosis. Similarly to IPF, a pattern of Th2 cytokine expression has also been identified in NSCLC. With respect to IL-13, a recent study observed the highest expression level of IL-13 in LC in the SQC subtype, followed by the ADC subtype. Moreover, a clear association between IL-13 receptor subunit alpha-2 overexpression and poor survival in resected NSCLC patients has been shown. There are other profibrotic cytokines besides IL-13 that are also associated with IPF. For example, chemokine ligand 2 (CCL2) has been reported to be present in the BALF of IPF patients at significant concentrations (Table 3). In IPF, CCL2 has been shown to induce the differentiation of developing T-cells into type 2 cells, and to stimulate collagen synthesis and TGFβ expression in lung fibroblasts. In LC, the CCL2/CCR2 (chemokine receptor type 2) axis is also important in several aspects of tumorigenesis. One of its most important roles is the generation of new vascular structures that allow tumour growth. However, there is evidence of an association between CCL2 in cancer cells and better survival in NSCLC patients.

4.4. Reactive Oxygen Species (ROS)

ROS production by ATII cells results in oxidative stress, which induces apoptosis of epithelial cells, activates intracellular signalling pathways, and upregulates the synthesis of profibrotic cytokines that ultimately leads to tissue injury and fibrosis. In this context, upregulation of NADPH oxidase 4 (NOX4) has been reported in pulmonary fibroblasts and other relevant cells in IPF. In the same way, NOX4 has been reported to be overexpressed in NSCLC (Table 3), contributing to cell proliferation and metastasis. Furthermore, following ROS overproduction, alterations in DNA methylation patterns and specific histone modifications lead to aberrant gene expression, and possibly trigger the multistage process of carcinogenesis. In addition, antioxidant molecules that mitigate oxidative stress, such as Nrf2, have also been reported to be dysregulated in both diseases (Table 3). As such, they are proposed to be future targets for anti-IPF/LC treatment.

4.5. Mucins

Significant overexpression of the secreted Mucin 5B (Muc5B) protein has been found in IPF lungs (Table 3) and it is hypothesised that excess Muc5B impairs the mucosal host defence; in turn, this may interfere with alveolar repair and leads to the development of idiopathic interstitial pneumonia. In this context, MUC5B expression has been associated with a high risk of distant metastasis in NSCLC patients and poorer prognosis in ADC patients.

We have also observed IPF overexpression of the transmembrane mucins, Muc1, Muc4, and Muc16 (unpublished data), which may be involved in the molecular processes that lead to the development of pulmonary fibrosis. In addition, the extracellular region of Muc1 contains the KL-6 epitope, which is proposed to be a useful biomarker for evaluating disease activity and predicting clinical outcomes in IPF. Similarly, these transmembrane mucins have previously been considered clinically relevant proteins that are aberrantly overexpressed in lung carcinogenesis. In fact, Muc1 is a target in several preclinical and clinical trials for cancer treatment. Concurrently, there is evidence that galectin 3 is a promising target for IPF because it has a profibrotic action that is partly mediated by binding to Muc1. Recently, the potential of galectin-3 as a therapeutic target in cancer has been highlighted since it is capable of modulating anti-tumour immunity.

4.6. Embryological Pathways

There is also evidence that some embryological pathways are reactivated or deregulated in fibrotic diseases (Table 3). For example, the Wnt/β-catenin pathway is overexpressed in the lung tissue of IPF and LC patients. This pathway regulates the expression of molecules involved in tissue invasion, such as matrilysin, laminin, and cyclin-D1, which induces the EMT process. Most importantly, this pathway is involved in biologically relevant cross talk with TGF-β.

The Sonic hedgehog (shh) pathway is also aberrantly activated in IPF, mainly in epithelial cells that line honeycomb cysts. The overexpression of the shh pathway promotes increased susceptibility to epithelial cell apoptosis and increased resistance to fibroblast apoptosis. This pathway is also reactivated at the early stage of oncogenesis by cancer stem cells and leads to paracrine action on other tumour cells, resulting in tumour growth, tumour spread, and EMT. In LC, reactivation of the shh pathway is involved in the development of resistance to all the main treatments of LC.

Finally, the Notch signalling pathway is also reactivated in AECs, induces α-SMA expression in fibroblasts, and mediates EMT in AECs. In the same way, abnormal expression of the members of the Notch signalling pathway is a relatively frequent event in patients with NSCLC. It has been demonstrated that members of the Notch signalling pathway may be potential biomarkers for predicting the progression and prognosis of patients with NSCLC. Furthermore, Notch signalling promotes the proliferation of NSCLC cells or inhibits apoptosis of NSCLC cells.

4.7. PI3K/AKT/mTOR Pathway

The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)-dependent pathway is dysregulated in fibroproliferative diseases, like pulmonary fibrosis (Table 3). In fact, overexpression of class I isoform p110γ in lung homogenates occurs in IPF patients, and has been shown to activate the downstream signalling of several key profibrotic growth factors implicated in IPF, including PDGF and TGFβ1, as well as abnormal proliferation of epithelial basal cells and TGF-β-induced fibroblast proliferation and differentiation. Moreover, it has been observed that the suppression of phosphatase and tensin homologue mediates matrix-mediated resistance to apoptosis. Phosphatase and tensin homologue are negative regulators of PI3K that in turn activate AKT. De-regulation of the PI3K/AKT/mTOR pathway is also involved in NSCLC and has been associated with high grade tumours and advanced disease. Furthermore, abnormalities in this pathway are more common in SQC than in ADC of the lung.

5.1. Genetic Alterations

Most pulmonary fibrosis patients who have a background of familial clustering of familial interstitial pneumonia show mutations in genes that encode surfactant-associated protein C (SFTPC), surfactant-associated protein A2 (SFTPA2), telomerase components (TERT and TERC), and genes associated with telomere biology, such as poly (a)-specific ribonuclease deadenylation nuclease (PARN) and regulator of telomere elongation helicase 1 (RTEL1). Further, several common variants in TERT, genomic regions near TERC, oligonucleotide-binding fold containing 1 (OBFC1), RTEL1, PARN, and toll-interacting protein (TOLLIP), have all been associated with a sporadic risk of developing IPF. Nevertheless, the most important genetic risk factor for sporadic IPF is a common variant (rs35705950) in the promoter region of the MUC5B gene, although it is also associated with familial pulmonary fibrosis (Table 4).

LC development is the result of a stepwise accumulation of multiple acquired mutations of tumour suppressor genes or candidates, and the overexpression and mutation of oncogenes (Table 4). In this context, multiple P53 gene mutations have been found during the early stage of bronchial carcinoma. Frequent P53 gene alterations have also been detected in epithelial lesions from IPF patients and in squamous metaplasia, distributed in the peripheral zone of the fibrotic area in patients with IPF. Similarly, aberration and loss of function of the candidate tumour suppressor gene fragile histidine triad (FHIT) has been reported in NSCLC, as well as in IPF lesions. Additionally, FHIT gene allelic loss has been seen more frequently among the metaplasias and bronchiolar epithelia samples obtained from LC-IPF patients than from IPF patients without LC. Otherwise, the frequency of expression of Ras protein in ATII cells has been observed as being significantly greater in lung tissues from LC-IPF patients compared with lung tissues from IPF patients who did not have lung carcinoma. Moreover, a specific point mutation in codon 12 of the KRAS gene has been detected in LC-IPF patients. Interestingly, this mutation has not been identified between the numerous KRAS mutations observed in lung carcinoma tissue. However, contrasting results regarding the prevalence of KRAS mutations in LC-IPF patients have been reported recently. In addition, a significantly higher prevalence of BRAF mutations in IPF-LC than in LC has been observed, with an equal distribution between ADC and SQC subtypes. Moreover, some of these somatic mutations have not been shown to be significant in NSCLC patients. As such, it is rational to suggest that these somatic mutations in tumour suppressor genes and oncogenes, as well as oncogene overexpression, predispose IPF patients to develop LC. However, it also raises two controversial questions: Why is LC not the cause, instead of a consequence, of IPF?; and why do LC and IPF not independently and synchronously develop as a result of common pathogenetic mechanisms? In answering these questions, Hwan et al. revealed a predominance of C>T somatic transitions in most of the somatic mutations detected in LC-IPF patients. By contrast, in the non-IPF SQC subtype, C>A transversions are the most frequent. This suggests a potential association between APOBEC (cytidine deaminase, which converts cytosine to uracil)-related mutagenesis and the development of LC associated with pulmonary fibrosis.

Recently, germline mutations associated with familial NSCLC and predisposing to it are also being discovered (Table 4). In this context, several findings suggest that some germline mutations that predispose patients to develop IPF also predispose them to developing lung carcinoma. Indeed, two heterozygous missense mutations, and a heterozygous missense mutation in SFTPA2 and SFTPA1, respectively, have been identified in LC-IPF families. All of these mutations are predicted to disrupt the structure of surfactant A protein (SP-A) and impair protein secretion, leading to protein instability and ER stress of resident ATII cells. SP-A is produced by ATII and club cells, which have both been proposed as possible initiators of lung ADC. Although the role of ER-stress in tumourigenesis is controversial, recent evidence showing that ER stress may attenuate senescence and promote tumorigenesis might explain the co-occurrence of LC (histological subtype ADC) and pulmonary fibrosis in families with an SFTPA1/2 mutation. Two further germline mutations in TERT (rs2736100) and CDKN1A (rs2395655), which were previously reported to confer IPF risk, have also been identified in several LC-IPF patients. These mutations affect telomerase function and impair the cellular response to DNA damage, respectively. Accordingly, they might also explain the co-occurrence of both diseases. Furthermore, the germline variant, rs2736100, has been reported to be associated with lung ADC risk, and other TERT, TERC, OFBC1, and RTEL1 polymorphisms have also been revealed as risk factors of LC. However, telomere functionality and its contribution to LC development is controversial. In fact, a gain at chromosomal region 5p15.33 in TERT is the most frequent genetic event in the early stages of NSCLC. However, short telomeres in peripheral blood leukocytes have been related to an increased risk of lung carcinoma, probably via an increased mutation rate and the genomic instability induced by telomere dysfunction. Therefore, it might be hypothesised that mutations associated with telomere biology in IPF lesions, which correlate with shortened telomeres in leukocytes and ATII cells, could drive the development of LC via an increased mutation rate and genomic instability.

Finally, the germline or somatic variant (rs35705950) in the MUC5B promoter region that consists of TT and GT genotypes (risk genotypes for IPF) has been reported to confer a survival advantage among patients with IPF. However, these genotypes are associated with poorer overall survival in NSCLC patients. Furthermore, significant associations between the MUC5B promoter polymorphism and the incidence of radiation pneumonitis in patients with NSCLC have not been identified. This supports the idea that IPF underlies the development of LC and is not a consequence of it.

5.2. Epigenetic Alterations

Due to similar pathogenic mechanisms between IPF and LC, their global methylation patterns are also somewhat similar (Table 4). However, there are also differences, which may be explained partly by IPF or cancer-specific changes. For example, it was found that as a consequence of promoter hypermethylation, the relative expression of the SMAD4 gene was significantly lower in the tumours of LC-IPF patients compared to those who had LC without IPF. This was a surprising finding because SMAD4 has been identified as a tumour-suppressor gene, but TGFβ1 signalling is the main effector in pulmonary fibrosis. Thus, SMAD4 over-expression would be expected in this disease. Another epigenetic alteration involved in IPF is THY-1 promoter hypermethylation and the absence of fibroblast Thy-1 expression, which is linked to the transformation of fibroblasts into myofibroblasts. Loss of this molecule has also been documented in cancer and is associated with a more invasive disease. By contrast, promoter hypermethylation of the O-6-methylguanine DNA methyltransferase (MGMT) gene is one of the early epigenetic marks in LC, while in IPF fibroblasts, MGMT is one of the most hypomethylated genes.

Otherwise, ~10% of miRNAs are abnormally expressed in IPF. These variations are all capable of influencing EMT and inducing the regulation of apoptosis or ECM. Some of these variations are also found in LC. For example, common to IPF, mir-21 is overexpressed in LC, which is an independent negative prognostic factor for overall survival in NSCLC patients. By contrast, Let-7d expression is found to be mostly down-regulated in IPF and LC and acts as an oncogene.

6. Therapeutic Management in Lung Cancer Associated with Pulmonary Fibrosis Patients

The focus of IPF treatment in previous decades has been to use anti-inflammatory/immunomodulatory drugs in combination with antioxidants. However, their therapeutic usefulness was recently questioned given the unfavourable outcome when N-acetyl L-cysteine (NAC) was used in combination with prednisolone/azathioprine. Following this, NAC monotherapy results were also negative, although a subgroup of IPF patients with the rs3750920 (TOLLIP) TT genotype showed a favourable response. Numerous cellular and preclinical studies hold that antioxidants protect against cancer. However, it has been shown that NAC increases tumour progression and reduces survival in LC preclinical models, which contraindicates NAC treatment for LC-IPF.

In line with the antioxidant treatments tested in IPF, pirfenidone was initially considered as an antioxidant therapy since it demonstrated O2− scavenging activity. Oral NAC has been used in conjunction with pirfenidone to treat IPF, but it does not substantially alter the tolerability profile of pirfenidone and is unlikely to be beneficial in IPF. Beyond its antioxidant activity, pirfenidone is a pleiotropic molecule that inhibits TGF−β, collagen synthesis, and fibroblast proliferation, and also mediates tissue repair. It is currently approved as an IPF therapy and Miuri et al. observed that the incidence of LC in IPF patients treated with pirfenidone was significantly lower than in a non-pirfenidone IPF patient group. Furthermore, recent publications have shown that pirfenidone confers anti-fibrotic effects by interfering with the shh pathway, which can partly explain the observed lower LC incidence in IPF patients treated with pirfenidone. It has also been observed that perioperative pirfenidone treatment reduces the incidence of postoperative acute exacerbation of IPF in LC-IPF patients. Moreover, experimental data have shown that the combination of pirfenidone and cisplatin may lead to an increase of CAF and tumour cell mortality in NSCLC preclinical models.

Advances in the understanding of IPF pathogenesis have resulted in further preclinical and clinical trials of drugs with antiproliferative and antifibrotic effects. For instance, tyrosine kinase inhibitors (TKIs), such as imatinib, nilotinib, gefitinib, erlotinib, nintedanib, SU5918, and SU11657, are being investigated. The important role of these inhibitors in cancer treatment was previously shown. Indeed, gefitinib and erlotinib are important oral treatments for NSCLC patients with mutations that activate the epidermal growth factor receptor (EGFR). In IPF, imatinib was tested in fibrotic patients, but failed to show any benefit on survival or lung function. In contrast, the VEGF, FGF, and PDGF receptor inhibitor, nintedanib, has been approved for IPF treatment. Additionally, this drug is also approved for use in combination with docetaxel as an effective second-line option for patients with advanced ADC-NSCLC who have been previously treated with one course of platinum-based therapy.

Another class of antifibrotic drugs are the mTOR kinase inhibitors, including everolimus, which failed as an IPF treatment. However, everolimus has shown modest beneficial effects in patients with advanced NSCLC who were previously treated with chemotherapy alone, or with chemotherapy and EGFR inhibitors. It is also approved as a second-line treatment in renal and breast cancer. Currently, there are efforts towards assessing the efficacy of a new mTOR kinase inhibitor (GSK-2126458) for IPF and advanced solid tumour treatment.

In addition to the previously mentioned therapeutic strategies, a broad range of IPF therapies are currently being tested in clinical trials (Table 5). Some of these therapies target molecules and mechanisms mentioned in this review, and which are hallmarks of the progression of both diseases. These include anti-IL-13 antibodies (QAX576 and Lebrikizumab), anti-CCL2 antibodies (Carlumab and CNTO-888), anti-TGFβ1 antibodies (Fresolimumab and GC1008), anti-integrin αvβ6 antibodies (BG0011 and STX-100), integrin αvβ6 antagonist drugs (GSK3008348), LPAR1 antagonist drugs (BMS-986020), ATX-inhibiting drugs (GLPG1690), angiostatic drugs (Tetrathiomolybdate), shh pathway-inhibiting drugs (vismodegib), and galectin-3-inhibiting drugs (TD139). Only two of these drugs are being clinically developed for NSCLC patients. Fresolimumab, which was tested in combination with stereotactic ablative radiotherapy in a phase I study, and tetrathiomolybdate in combination with carboplatin and pemetrexed, which is currently being tested in a phase I study. There are also preclinical studies for NSCLC that include some of these target molecules. For example, CCR2 antagonism was demonstrated to supress CCL2-mediated viability, motility, and invasion of the NSCLC cell line, A549, in vitro. Likewise, galectin-3 knockdown in NSCLC cell line-derived sphere resulted in attenuation of lung carcinogenesis by inhibiting stem-like properties. In the same way, genetic deletion of ATX and LPAR1 was shown to attenuate lung carcinogenesis development in animal models. Moreover, vismodegib is approved for the treatment of metastatic, local, or recurrent advanced basal cell carcinoma (BCC), although it has not been tested in NSCLC. Nevertheless, blockade of shh signaling synergistically has shown to increase sensitivity to EGFR-TKIs in primary and secondary resistant NSCLC cells.

Given the mechanistic similarities between LC and IPF diseases, and the concurrence of predominantly NSCLC and IPF, it is rational to consider the usefulness of the large number of approved NSCLC treatments for the management of pulmonary fibrosis. For example, Nivolumab is a new immunomodulatory agent that acts as a programmed death receptor-1-blocking antibody. One case study of an ADC patient with IPF showed a beneficial and sustained response in the lung, without any sign of IPF exacerbation after Nivolumab treatment. This could be explained by the higher expression of programmed cell death ligand 1 reported in cancer cells from UIP-associated SQC versus non-UIP SQC patients. Other examples of feasible IPF and LC-IPF treatment candidates include vantictumab, which interferes with Wnt signalling and has undergone Phase I trials for NSCLC (preclinical studies of Wnt pathway inhibition have also been performed in pulmonary fibrosis), and Muc1-based therapeutic strategies. Indeed, four Muc1-based Phase III trials exploring cancer treatment have been completed, one of which used a Muc1 tandem repeat peptide as an immunogen (L-BLP25) in patients with stage III unresectable NSCLC after chemoradiation.

Finally, rovalpituzumab treatment, although not tested for NSCLC, is currently approved for SCLC, and it could also have potential in the treatment of IPF and LC-IPF, since it interferes with the Notch signalling pathway. In fact, it has been observed that artesunate ameliorates lung fibrosis via inhibiting the Notch signaling pathway in a rat bleomycin model.

7. Conclusions

The course of IPF disease and its resulting mortality are altered by the frequent co-occurrence of LC. This review supports the view of LC as a consequence of a genetic predisposition in IPF patients and, common cellular processes and molecular pathways between both diseases. Currently, there is no consensus regarding the treatment of patients with both diseases. However, pirfenidone and nintedanib are two novel drugs approved for IPF that have potential for treating patients with fibrosis, possibly extending the survival time and lowering the incidence of LC. However, we are some distance from realising effective therapeutic approaches that are capable of stopping the disease process, where disease progression still occurs in most IPF patients despite treatment. Nevertheless, we now have a great deal of knowledge about cancer biology and its similarities with IPF. Therefore, it seems reasonable to investigate whether specific cancer drugs may exert beneficial anti-fibrotic effects that are effective to treat LC-IPF patients. Furthermore, clinical trials that prospectively investigate the efficacy of currently approved anti-fibrotic agents (or agents under study) as treatments for LC-IPF patients are sorely needed.

References 262

  1. 1.

    Raghu G., Collard H.R., Egan J.J., Martinez F.J., Behr J., Brown K.K., Colby T.V., Cordier J.F., Flaherty K.R., Lasky J.A., et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011;183:788-824.

    Not in our library10.1164/rccm.2009-040gl

  2. 2.

    Ley B., Collard H.R., King T.E. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011;183:431-440.

    Not in our library10.1164/rccm.201006-0894ci

  3. 3.

    Meyer E.C., Liebow A.A. Relationship of Interstitial Pneumonia Honeycombing and Atypical Epithelial Proliferation to Cancer of the Lung. Cancer. 1965;18:322-351.

    Not in our library10.1002/1097-0142(196503)18:3<322::aid-cncr2820180310>3.0.co;2-j

  4. 4.

    Karampitsakos T., Tzilas V., Tringidou R., Steiropoulos P., Aidinis V., Papiris S.A., Bouros D., Tzouvelekis A. Lung cancer in patients with idiopathic pulmonary fibrosis. Pulm. Pharmacol. Ther. 2017;45:1-10.

    Not in our library10.1016/j.pupt.2017.03.016

  5. 5.

    Hubbard R., Venn A., Lewis S., Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am. J. Respir. Crit. Care Med. 2000;161:5-8.

    Not in our library10.1164/ajrccm.161.1.9906062

  6. 6.

    Wells C., Mannino D.M. Pulmonary fibrosis and lung cancer in the United States: Analysis of the multiple cause of death mortality data, 1979 through 1991. South. Med J. 1996;89:505-510.

    Not in our library10.1097/00007611-199605000-00012

  7. 7.

    Artinian V., Kvale P.A. Cancer and interstitial lung disease. Curr. Opin. Pulm. Med. 2004;10:425-434.

    Not in our library10.1097/00063198-200409000-00017

  8. 8.

    Kato E., Takayanagi N., Takaku Y., Kagiyama N., Kanauchi T., Ishiguro T., Sugita Y. Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis. ERJ Open Res. 2018;4:00111-2016.

    Not in our library10.1183/23120541.00111-2016

  9. 9.

    Nagai A., Chiyotani A., Nakadate T., Konno K. Lung cancer in patients with idiopathic pulmonary fibrosis. Tohoku J. Exp. Med. 1992;167:231-237.

    Not in our library10.1620/tjem.167.231

  10. 10.

    Aubry M.C., Myers J.L., Douglas W.W., Tazelaar H.D., Washington Stephens T.L., Hartman T.E., Deschamps C., Pankratz V.S. Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis. Mayo Clin. Proc. 2002;77:763-770.

    Not in our library10.4065/77.8.763

  11. 11.

    Usui K., Tanai C., Tanaka Y., Noda H., Ishihara T. The prevalence of pulmonary fibrosis combined with emphysema in patients with lung cancer. Respirology. 2011;16:326-331.

    Not in our library10.1111/j.1440-1843.2010.01907.x

  12. 12.

    JafariNezhad A., YektaKooshali M.H. Lung cancer in idiopathic pulmonary fibrosis: A systematic review and meta-analysis. PLoS ONE. 2018;13:e0202360.

    Not in our library10.1371/journal.pone.0202360

  13. 13.

    Matsushita H., Tanaka S., Saiki Y., Hara M., Nakata K., Tanimura S., Banba J. Lung cancer associated with usual interstitial pneumonia. Pathol. Int. 1995;45:925-932.

    Not in our library10.1111/j.1440-1827.1995.tb03417.x

  14. 14.

    Park J., Kim D.S., Shim T.S., Lim C.M., Koh Y., Lee S.D., Kim W.S., Kim W.D., Lee J.S., Song K.S. Lung cancer in patients with idiopathic pulmonary fibrosis. Eur. Respir. J. 2001;17:1216-1219.

    Not in our library10.1183/09031936.01.99055301

  15. 15.

    Ozawa Y., Suda T., Naito T., Enomoto N., Hashimoto D., Fujisawa T., Nakamura Y., Inui N., Nakamura H., Chida K. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology. 2009;14:723-728.

    Not in our library10.1111/j.1440-1843.2009.01547.x

  16. 16.

    Lee K.J., Chung M.P., Kim Y.W., Lee J.H., Kim K.S., Ryu J.S., Lee H.L., Park S.W., Park C.S., Uh S.T., et al. Prevalence, risk factors and survival of lung cancer in the idiopathic pulmonary fibrosis. Thorac. Cancer. 2012;3:150-155.

    Not in our library10.1111/j.1759-7714.2011.00107.x

  17. 17.

    Kreuter M., Ehlers-Tenenbaum S., Schaaf M., Oltmanns U., Palmowski K., Hoffmann H., Schnabel P.A., Heussel C.P., Puderbach M., Herth F.J., et al. Treatment and outcome of lung cancer in idiopathic interstitial pneumonias. Sarcoidosis Vasc. Diffus. Lung Dis. Off. J. WASOG. 2015;31:266-274.

    Not in our library

  18. 18.

    Tomassetti S., Gurioli C., Ryu J.H., Decker P.A., Ravaglia C., Tantalocco P., Buccioli M., Piciucchi S., Sverzellati N., Dubini A., et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest. 2015;147:157-164.

    Not in our library10.1378/chest.14-0359

  19. 19.

    Yoon J.H., Nouraie M., Chen X., Zou R.H., Sellares J., Veraldi K.L., Chiarchiaro J., Lindell K., Wilson D.O., Kaminski N., et al. Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease—Analysis of institutional and population data. Respir. Res. 2018;19:195.

    Not in our library10.1186/s12931-018-0899-4

  20. 20.

    Le Jeune I., Gribbin J., West J., Smith C., Cullinan P., Hubbard R. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir. Med. 2007;101:2534-2540.

    Not in our library10.1016/j.rmed.2007.07.012

  21. 21.

    Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136:E359-E386.

    Not in our library10.1002/ijc.29210

  22. 22.

    Hyldgaard C., Hilberg O., Bendstrup E. How does comorbidity influence survival in idiopathic pulmonary fibrosis? Respir. Med. 2014;108:647-653.

    Not in our library10.1016/j.rmed.2014.01.008

  23. 23.

    Dela Cruz C.S., Tanoue L.T., Matthay R.A. Lung cancer: Epidemiology, etiology, and prevention. Clin. Chest Med. 2011;32:605-644.

    Not in our library10.1016/j.ccm.2011.09.001

  24. 24.

    Kawai T., Yakumaru K., Suzuki M., Kageyama K. Diffuse interstitial pulmonary fibrosis and lung cancer. Acta Pathol. Jpn. 1987;37:11-19.

    Not in our library10.1111/j.1440-1827.1987.tb03130.x

  25. 25.

    Kawasaki H., Nagai K., Yokose T., Yoshida J., Nishimura M., Takahashi K., Suzuki K., Kakinuma R., Nishiwaki Y. Clinicopathological characteristics of surgically resected lung cancer associated with idiopathic pulmonary fibrosis. J. Surg. Oncol. 2001;76:53-57.

    Not in our library10.1002/1096-9098(200101)76:1<53::aid-jso1009>3.0.co;2-t

  26. 26.

    Saito Y., Kawai Y., Takahashi N., Ikeya T., Murai K., Kawabata Y., Hoshi E. Survival after surgery for pathologic stage IA non-small cell lung cancer associated with idiopathic pulmonary fibrosis. Ann. Thorac. Surg. 2011;92:1812-1817.

    Not in our library10.1016/j.athoracsur.2011.06.055

  27. 27.

    Lee T., Park J.Y., Lee H.Y., Cho Y.J., Yoon H.I., Lee J.H., Jheon S., Lee C.T., Park J.S. Lung cancer in patients with idiopathic pulmonary fibrosis: Clinical characteristics and impact on survival. Respir. Med. 2014;108:1549-1555.

    Not in our library10.1016/j.rmed.2014.07.020

  28. 28.

    Khan K.A., Kennedy M.P., Moore E., Crush L., Prendeville S., Maher M.M., Burke L., Henry M.T. Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis. Lung. 2015;193:71-77.

    Not in our library10.1007/s00408-014-9664-8

  29. 29.

    Guyard A., Danel C., Theou-Anton N., Debray M.P., Gibault L., Mordant P., Castier Y., Crestani B., Zalcman G., Blons H., et al. Morphologic and molecular study of lung cancers associated with idiopathic pulmonary fibrosis and other pulmonary fibroses. Respir. Res. 2017;18:120.

    Not in our library10.1186/s12931-017-0605-y

  30. 30.

    Fraire A.E., Greenberg S.D. Carcinoma and diffuse interstitial fibrosis of lung. Cancer. 1973;31:1078-1086.

    Not in our library10.1002/1097-0142(197305)31:5<1078::aid-cncr2820310507>3.0.co;2-1

  31. 31.

    Shimizu H. Pathological study of lung cancer associated with idiopathic interstitial pneumonia—With special reference to relationship between the primary site of lung cancer and honeycombing. Nihon Kyobu Shikkan Gakkai Zasshi. 1985;23:873-881.

    Not in our library

  32. 32.

    Mizushima Y., Kobayashi M. Clinical characteristics of synchronous multiple lung cancer associated with idiopathic pulmonary fibrosis. A review of Japanese cases. Chest. 1995;108:1272-1277.

    Not in our library10.1378/chest.108.5.1272

  33. 33.

    Calio A., Lever V., Rossi A., Gilioli E., Brunelli M., Dubini A., Tomassetti S., Piciucchi S., Nottegar A., Rossi G., et al. Increased frequency of bronchiolar histotypes in lung carcinomas associated with idiopathic pulmonary fibrosis. Histopathology. 2017;71:725-735.

    Not in our library10.1111/his.13269

  34. 34.

    Strock S.B., Alder J.K., Kass D.J. From bad to worse: When lung cancer complicates idiopathic pulmonary fibrosis. J. Pathol. 2018;244:383-385.

    Not in our library10.1002/path.5027

  35. 35.

    Bargagli E., Bonti V., Ferrari K., Rosi E., Bindi A., Bartolucci M., Chiara M., Voltolini L. Lung Cancer in Patients with Severe Idiopathic Pulmonary Fibrosis: Critical Aspects. In Vivo. 2017;31:773-777.

    Not in our library10.21873/invivo.11130

  36. 36.

    Hironaka M., Fukayama M. Pulmonary fibrosis and lung carcinoma: A comparative study of metaplastic epithelia in honeycombed areas of usual interstitial pneumonia with or without lung carcinoma. Pathol. Int. 1999;49:1060-1066.

    Not in our library10.1046/j.1440-1827.1999.00989.x

  37. 37.

    Scotton C.J., Chambers R.C. Molecular targets in pulmonary fibrosis: The myofibroblast in focus. Chest. 2007;132:1311-1321.

    Not in our library10.1378/chest.06-2568

  38. 38.

    Singh S.R., Hall I.P. Airway myofibroblasts and their relationship with airway myocytes and fibroblasts. Proc. Am. Thorac. Soc. 2008;5:127-132.

    Not in our library10.1513/pats.200706-070vs

  39. 39.

    Thannickal V.J., Toews G.B., White E.S., Lynch J.P., Martinez F.J. Mechanisms of pulmonary fibrosis. Annu. Rev. Med. 2004;55:395-417.

    Not in our library10.1146/annurev.med.55.091902.103810

  40. 40.

    Evans J.N., Kelley J., Krill J., Low R.B., Adler K.B. The myofibroblast in pulmonary fibrosis. Chest. 1983;83:97S-98S.

    Not in our library10.1378/chest.83.5_supplement.97s

  41. 41.
    TGF-β1 induces human alveolar epithelial to mesenchymal cell transition (EMT) · 2005
    No notice
  42. 42.

    Yao H.W., Xie Q.M., Chen J.Q., Deng Y.M., Tang H.F. TGF-beta1 induces alveolar epithelial to mesenchymal transition in vitro. Life Sci. 2004;76:29-37.

    Not in our library10.1016/j.lfs.2004.06.019

  43. 43.

    Willis B.C., Liebler J.M., Luby-Phelps K., Nicholson A.G., Crandall E.D., du Bois R.M., Borok Z. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: Potential role in idiopathic pulmonary fibrosis. Am. J. Pathol. 2005;166:1321-1332.

    Not in our library10.1016/s0002-9440(10)62351-6

  44. 44.

    Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 2009;119:1420-1428.

    Not in our library10.1172/jci39104

  45. 45.

    Mehrad B., Strieter R.M. Fibrocytes and the pathogenesis of diffuse parenchymal lung disease. Fibrogenesis Tissue Repair. 2012;5(Suppl. 1):S22.

    Not in our library10.1186/1755-1536-5-s1-s22

  46. 46.

    Strieter R.M. Pathogenesis and natural history of usual interstitial pneumonia: The whole story or the last chapter of a long novel. Chest. 2005;128:526S-532S.

    Not in our library10.1378/chest.128.5_suppl_1.526s

  47. 47.

    Metz C.N. Fibrocytes: A unique cell population implicated in wound healing. Cell. Mol. Life Sci. CMLS. 2003;60:1342-1350.

    Not in our library10.1007/s00018-003-2328-0

  48. 48.

    Phillips R.J., Burdick M.D., Hong K., Lutz M.A., Murray L.A., Xue Y.Y., Belperio J.A., Keane M.P., Strieter R.M. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J. Clin. Investig. 2004;114:438-446.

    Not in our library10.1172/jci200420997

  49. 49.

    Schmidt M., Sun G., Stacey M.A., Mori L., Mattoli S. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J. Immunol. 2003;171:380-389.

    Not in our library10.4049/jimmunol.171.1.380

  50. 50.

    Almudever P., Milara J., De Diego A., Serrano-Mollar A., Xaubet A., Perez-Vizcaino F., Cogolludo A., Cortijo J. Role of tetrahydrobiopterin in pulmonary vascular remodelling associated with pulmonary fibrosis. Thorax. 2013;68:938-948.

    Not in our library10.1136/thoraxjnl-2013-203408

  51. 51.

    Nataraj D., Ernst A., Kalluri R. Idiopathic pulmonary fibrosis is associated with endothelial to mesenchymal transition. Am. J. Respir. Cell Mol. Biol. 2010;43:129-130.

    Not in our library10.1165/rcmb.2010-0044ed

  52. 52.

    Fernandez I.E., Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet. 2012;380:680-688.

    Not in our library10.1016/s0140-6736(12)61144-1

  53. 53.

    Hung C., Linn G., Chow Y.H., Kobayashi A., Mittelsteadt K., Altemeier W.A., Gharib S.A., Schnapp L.M., Duffield J.S. Role of lung pericytes and resident fibroblasts in the pathogenesis of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2013;188:820-830.

    Not in our library10.1164/rccm.201212-2297oc

  54. 54.

    Zolak J.S., Jagirdar R., Surolia R., Karki S., Oliva O., Hock T., Guroji P., Ding Q., Liu R.M., Bolisetty S., et al. Pleural mesothelial cell differentiation and invasion in fibrogenic lung injury. Am. J. Pathol. 2013;182:1239-1247.

    Not in our library10.1016/j.ajpath.2012.12.030

  55. 55.

    Nasreen N., Mohammed K.A., Mubarak K.K., Baz M.A., Akindipe O.A., Fernandez-Bussy S., Antony V.B. Pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to TGF-beta1 in vitro. Am. J. Physiol. Lung Cell. Mol. Physiol. 2009;297:L115-L124.

    Not in our library10.1152/ajplung.90587.2008

  56. 56.

    Mubarak K.K., Montes-Worboys A., Regev D., Nasreen N., Mohammed K.A., Faruqi I., Hensel E., Baz M.A., Akindipe O.A., Fernandez-Bussy S., et al. Parenchymal trafficking of pleural mesothelial cells in idiopathic pulmonary fibrosis. Eur. Respir. J. 2012;39:133-140.

    Not in our library10.1183/09031936.00141010

  57. 57.

    Horowitz J.C., Osterholzer J.J., Marazioti A., Stathopoulos G.T. “Scar-cinoma”: Viewing the fibrotic lung mesenchymal cell in the context of cancer biology. Eur. Respir. J. 2016;47:1842-1854.

    Not in our library10.1183/13993003.01201-2015

  58. 58.

    Kalluri R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer. 2016;16:582-598.

    Not in our library10.1038/nrc.2016.73

  59. 59.

    Konigshoff M. Lung cancer in pulmonary fibrosis: Tales of epithelial cell plasticity. Respir. Int. Rev. Thorac. Dis. 2011;81:353-358.

    Not in our library10.1159/000326299

  60. 60.

    Direkze N.C., Hodivala-Dilke K., Jeffery R., Hunt T., Poulsom R., Oukrif D., Alison M.R., Wright N.A. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res. 2004;64:8492-8495.

    Not in our library10.1158/0008-5472.can-04-1708

  61. 61.
    Cancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth · 2015
    No notice
  62. 62.

    Zeisberg E.M., Potenta S., Xie L., Zeisberg M., Kalluri R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 2007;67:10123-10128.

    Not in our library10.1158/0008-5472.can-07-3127

  63. 63.

    Hosaka K., Yang Y., Seki T., Fischer C., Dubey O., Fredlund E., Hartman J., Religa P., Morikawa H., Ishii Y., et al. Pericyte-fibroblast transition promotes tumor growth and metastasis. Proc. Natl. Acad. Sci. USA. 2016;113:E5618-E5627.

    Not in our library10.1073/pnas.1608384113

  64. 64.

    Rinkevich Y., Mori T., Sahoo D., Xu P.X., Bermingham J.R., Weissman I.L. Identification and prospective isolation of a mesothelial precursor lineage giving rise to smooth muscle cells and fibroblasts for mammalian internal organs, and their vasculature. Nat. Cell Biol. 2012;14:1251-1260.

    Not in our library10.1038/ncb2610

  65. 65.

    Tanjore H., Blackwell T.S., Lawson W.E. Emerging evidence for endoplasmic reticulum stress in the pathogenesis of idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2012;302:L721-L729.

    Not in our library10.1152/ajplung.00410.2011

  66. 66.

    Wolters P.J., Collard H.R., Jones K.D. Pathogenesis of Idiopathic Pulmonary Fibrosis. Annu. Rev. Pathol. 2013.

    Not in our library10.1146/annurev-pathol-012513-104706

  67. 67.

    Thannickal V.J., Horowitz J.C. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc. Am. Thorac. Soc. 2006;3:350-356.

    Not in our library10.1513/pats.200601-001tk

  68. 68.

    Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell. 2011;144:646-674.

    Not in our library10.1016/j.cell.2011.02.013

  69. 69.

    Tsai Y.C., Weissman A.M. The Unfolded Protein Response, Degradation from Endoplasmic Reticulum and Cancer. Genes Cancer. 2010;1:764-778.

    Not in our library10.1177/1947601910383011

  70. 70.

    Lin J.H., Walter P., Yen T.S. Endoplasmic reticulum stress in disease pathogenesis. Annu. Rev. Pathol. 2008;3:399-425.

    Not in our library10.1146/annurev.pathmechdis.3.121806.151434

  71. 71.

    Zhu B., Ferry C.H., Markell L.K., Blazanin N., Glick A.B., Gonzalez F.J., Peters J.M. The nuclear receptor peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) promotes oncogene-induced cellular senescence through repression of endoplasmic reticulum stress. J. Biol. Chem. 2014;289:20102-20119.

    Not in our library10.1074/jbc.m114.551069

  72. 72.

    Araya J., Kojima J., Takasaka N., Ito S., Fujii S., Hara H., Yanagisawa H., Kobayashi K., Tsurushige C., Kawaishi M., et al. Insufficient autophagy in idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2013;304:L56-L69.

    Not in our library10.1152/ajplung.00213.2012

  73. 73.
    Autophagy in Idiopathic Pulmonary Fibrosis · 2012
    No notice
  74. 74.
    Deregulation of selective autophagy during aging and pulmonary fibrosis: the role of TGF β1 · 2015
    No notice
  75. 75.

    Del Principe D., Vona R., Giordani L., Straface E., Giammarioli A.M. Defective autophagy in fibroblasts may contribute to fibrogenesis in autoimmune processes. Curr. Pharm. Des. 2011;17:3878-3887.

    Not in our library10.2174/138161211798357791

  76. 76.

    Marino G., Niso-Santano M., Baehrecke E.H., Kroemer G. Self-consumption: The interplay of autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 2014;15:81-94.

    Not in our library10.1038/nrm3735

  77. 77.

    White E. The role for autophagy in cancer. J. Clin. Investig. 2015;125:42-46.

    Not in our library10.1172/jci73941

  78. 78.

    Levy J.M.M., Towers C.G., Thorburn A. Targeting autophagy in cancer. Nat. Rev. Cancer. 2017;17:528-542.

    Not in our library10.1038/nrc.2017.53

  79. 79.

    Vancheri C., Sortino M.A., Tomaselli V., Mastruzzo C., Condorelli F., Bellistri G., Pistorio M.P., Canonico P.L., Crimi N. Different expression of TNF-alpha receptors and prostaglandin E(2)Production in normal and fibrotic lung fibroblasts: Potential implications for the evolution of the inflammatory process. Am. J. Respir. Cell Mol. Biol. 2000;22:628-634.

    Not in our library10.1165/ajrcmb.22.5.3948

  80. 80.

    Moore B.B., Ballinger M.N., White E.S., Green M.E., Herrygers A.B., Wilke C.A., Toews G.B., Peters-Golden M. Bleomycin-induced E prostanoid receptor changes alter fibroblast responses to prostaglandin E2. J. Immunol. 2005;174:5644-5649.

    Not in our library10.4049/jimmunol.174.9.5644

  81. 81.

    Nho R.S., Hergert P., Kahm J., Jessurun J., Henke C. Pathological alteration of FoxO3a activity promotes idiopathic pulmonary fibrosis fibroblast proliferation on type i collagen matrix. Am. J. Pathol. 2011;179:2420-2430.

    Not in our library10.1016/j.ajpath.2011.07.020

  82. 82.

    Grimminger F., Gunther A., Vancheri C. The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. Eur. Respir. J. 2015;45:1426-1433.

    Not in our library10.1183/09031936.00149614

  83. 83.

    Ramos C., Montano M., Garcia-Alvarez J., Ruiz V., Uhal B.D., Selman M., Pardo A. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am. J. Respir. Cell Mol. Biol. 2001;24:591-598.

    Not in our library10.1165/ajrcmb.24.5.4333

  84. 84.

    Mio T., Nagai S., Kitaichi M., Kawatani A., Izumi T. Proliferative characteristics of fibroblast lines derived from open lung biopsy specimens of patients with IPF (UIP). Chest. 1992;102:832-837.

    Not in our library10.1378/chest.102.3.832

  85. 85.

    Raghu G., Chen Y.Y., Rusch V., Rabinovitch P.S. Differential proliferation of fibroblasts cultured from normal and fibrotic human lungs. Am. Rev. Respir. Dis. 1988;138:703-708.

    Not in our library10.1164/ajrccm/138.3.703

  86. 86.

    Losa D., Chanson M., Crespin S. Connexins as therapeutic targets in lung disease. Expert Opin. Ther. Targets. 2011;15:989-1002.

    Not in our library10.1517/14728222.2011.584875

  87. 87.

    Trovato-Salinaro A., Trovato-Salinaro E., Failla M., Mastruzzo C., Tomaselli V., Gili E., Crimi N., Condorelli D.F., Vancheri C. Altered intercellular communication in lung fibroblast cultures from patients with idiopathic pulmonary fibrosis. Respir. Res. 2006;7:122.

    Not in our library10.1186/1465-9921-7-122

  88. 88.

    Cesen-Cummings K., Fernstrom M.J., Malkinson A.M., Ruch R.J. Frequent reduction of gap junctional intercellular communication and connexin43 expression in human and mouse lung carcinoma cells. Carcinogenesis. 1998;19:61-67.

    Not in our library10.1093/carcin/19.1.61

  89. 89.
    Cellular senescence mediates fibrotic pulmonary disease · 2017
    No notice
  90. 90.

    Selman M., Pardo A. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model. Am. J. Respir. Crit. Care Med. 2014;189:1161-1172.

    Not in our library10.1164/rccm.201312-2221pp

  91. 91.

    Dimri G.P. What has senescence got to do with cancer? Cancer Cell. 2005;7:505-512.

    Not in our library10.1016/j.ccr.2005.05.025

  92. 92.

    Krtolica A., Parrinello S., Lockett S., Desprez P.Y., Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: A link between cancer and aging. Proc. Natl. Acad. Sci. USA. 2001;98:12072-12077.

    Not in our library10.1073/pnas.211053698

  93. 93.

    White E.S., Thannickal V.J., Carskadon S.L., Dickie E.G., Livant D.L., Markwart S., Toews G.B., Arenberg D.A. Integrin alpha4beta1 regulates migration across basement membranes by lung fibroblasts: A role for phosphatase and tensin homologue deleted on chromosome 10. Am. J. Respir. Crit. Care Med. 2003;168:436-442.

    Not in our library10.1164/rccm.200301-041oc

  94. 94.

    Lovgren A.K., Kovacs J.J., Xie T., Potts E.N., Li Y., Foster W.M., Liang J., Meltzer E.B., Jiang D., Lefkowitz R.J., et al. beta-arrestin deficiency protects against pulmonary fibrosis in mice and prevents fibroblast invasion of extracellular matrix. Sci. Transl. Med. 2011;3:74ra23.

    Not in our library10.1126/scitranslmed.3001564

  95. 95.

    Vancheri C. Common pathways in idiopathic pulmonary fibrosis and cancer. Eur. Respir. Rev. Off. J. Eur. Respir. Soc. 2013;22:265-272.

    Not in our library10.1183/09059180.00003613

  96. 96.

    Moriya Y., Niki T., Yamada T., Matsuno Y., Kondo H., Hirohashi S. Increased expression of laminin-5 and its prognostic significance in lung adenocarcinomas of small size. An immunohistochemical analysis of 102 cases. Cancer. 2001;91:1129-1141.

    Not in our library10.1002/1097-0142(20010315)91:6<1129::aid-cncr1109>3.0.co;2-c

  97. 97.

    Garrido C., Schmitt E., Cande C., Vahsen N., Parcellier A., Kroemer G. HSP27 and HSP70: Potentially oncogenic apoptosis inhibitors. Cell Cycle. 2003;2:579-584.

    Not in our library10.4161/cc.2.6.521

  98. 98.
    Independent prognostic value of fascin immunoreactivity in stage I nonsmall cell lung cancer · 2003
    No notice
  99. 99.

    Chilosi M., Zamo A., Doglioni C., Reghellin D., Lestani M., Montagna L., Pedron S., Ennas M.G., Cancellieri A., Murer B., et al. Migratory marker expression in fibroblast foci of idiopathic pulmonary fibrosis. Respir. Res. 2006;7:95.

    Not in our library10.1186/1465-9921-7-95

  100. 100.
    Macrophages: friend or foe in idiopathic pulmonary fibrosis? · 2018
    No notice
  101. 101.

    Barron L., Wynn T.A. Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. Am. J. Physiol. Gastrointest. Liver Physiol. 2011;300:G723-G728.

    Not in our library10.1152/ajpgi.00414.2010

  102. 102.

    Ballinger M.N., Newstead M.W., Zeng X., Bhan U., Mo X.M., Kunkel S.L., Moore B.B., Flavell R., Christman J.W., Standiford T.J. IRAK-M promotes alternative macrophage activation and fibroproliferation in bleomycin-induced lung injury. J. Immunol. 2015;194:1894-1904.

    Not in our library10.4049/jimmunol.1402377

  103. 103.

    Osterholzer J.J., Olszewski M.A., Murdock B.J., Chen G.H., Erb-Downward J.R., Subbotina N., Browning K., Lin Y., Morey R.E., Dayrit J.K., et al. Implicating exudate macrophages and Ly-6C(high) monocytes in CCR2-dependent lung fibrosis following gene-targeted alveolar injury. J. Immunol. 2013;190:3447-3457.

    Not in our library10.4049/jimmunol.1200604

  104. 104.

    Craig V.J., Zhang L., Hagood J.S., Owen C.A. Matrix metalloproteinases as therapeutic targets for idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2015;53:585-600.

    Not in our library10.1165/rcmb.2015-0020tr

  105. 105.

    Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011;11:723-737.

    Not in our library10.1038/nri3073

  106. 106.

    Noy R., Pollard J.W. Tumor-associated macrophages: From mechanisms to therapy. Immunity. 2014;41:49-61.

    Not in our library10.1016/j.immuni.2014.06.010

  107. 107.

    Akhurst R.J., Hata A. Targeting the TGFbeta signalling pathway in disease. Nat. Rev. Drug Discov. 2012;11:790-811.

    Not in our library10.1038/nrd3810

  108. 108.

    Kelly M., Kolb M., Bonniaud P., Gauldie J. Re-evaluation of fibrogenic cytokines in lung fibrosis. Curr. Pharm. Des. 2003;9:39-49.

    Not in our library10.2174/1381612033392341

  109. 109.

    O’Riordan T.G., Smith V., Raghu G. Development of novel agents for idiopathic pulmonary fibrosis: Progress in target selection and clinical trial design. Chest. 2015;148:1083-1092.

    Not in our library10.1378/chest.14-3218

  110. 110.

    Roberts A.B., Wakefield L.M. The two faces of transforming growth factor beta in carcinogenesis. Proc. Natl. Acad. Sci. USA. 2003;100:8621-8623.

    Not in our library10.1073/pnas.1633291100

  111. 111.

    Hetzel M., Bachem M., Anders D., Trischler G., Faehling M. Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts. Lung. 2005;183:225-237.

    Not in our library10.1007/s00408-004-2534-z

  112. 112.

    Bonner J.C. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Fact. Rev. 2004;15:255-273.

    Not in our library10.1016/j.cytogfr.2004.03.006

  113. 113.

    Noskovicova N., Petrek M., Eickelberg O., Heinzelmann K. Platelet-derived growth factor signaling in the lung. From lung development and disease to clinical studies. Am. J. Respir. Cell Mol. Biol. 2015;52:263-284.

    Not in our library10.1165/rcmb.2014-0294tr

  114. 114.

    Battegay E.J., Raines E.W., Seifert R.A., Bowen-Pope D.F., Ross R. TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell. 1990;63:515-524.

    Not in our library10.1016/0092-8674(90)90448-n

  115. 115.

    Battegay E.J., Raines E.W., Colbert T., Ross R. TNF-alpha stimulation of fibroblast proliferation. Dependence on platelet-derived growth factor (PDGF) secretion and alteration of PDGF receptor expression. J. Immunol. 1995;154:6040-6047.

    Not in our library

  116. 116.

    Wang P., Song L., Ge H., Jin P., Jiang Y., Hu W., Geng N. Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo. Oncotargets Ther. 2014;7:1761-1768.

    Not in our library10.2147/ott.s68773

  117. 117.

    Shikada Y., Yonemitsu Y., Koga T., Onimaru M., Nakano T., Okano S., Sata S., Nakagawa K., Yoshino I., Maehara Y., et al. Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas. Cancer Res. 2005;65:7241-7248.

    Not in our library10.1158/0008-5472.can-04-4171

  118. 118.

    Chaudhary N.I., Roth G.J., Hilberg F., Muller-Quernheim J., Prasse A., Zissel G., Schnapp A., Park J.E. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur. Respir. J. 2007;29:976-985.

    Not in our library10.1183/09031936.00152106

  119. 119.

    Frezzetti D., Gallo M., Maiello M.R., D’Alessio A., Esposito C., Chicchinelli N., Normanno N., De Luca A. VEGF as a potential target in lung cancer. Expert Opin. Ther. Targets. 2017;21:959-966.

    Not in our library10.1080/14728222.2017.1371137

  120. 120.

    Zhang S., Smartt H., Holgate S.T., Roche W.R. Growth factors secreted by bronchial epithelial cells control myofibroblast proliferation: An in vitro co-culture model of airway remodeling in asthma. Lab. Investig. A J. Tech. Methods Pathol. 1999;79:395-405.

    Not in our library

  121. 121.

    Khalil N., Xu Y.D., O’Connor R., Duronio V. Proliferation of pulmonary interstitial fibroblasts is mediated by transforming growth factor-beta1-induced release of extracellular fibroblast growth factor-2 and phosphorylation of p38 MAPK and JNK. J. Biol. Chem. 2005;280:43000-43009.

    Not in our library10.1074/jbc.m510441200

  122. 122.

    Guzy R.D., Li L., Smith C., Dorry S.J., Koo H.Y., Chen L., Ornitz D.M. Pulmonary fibrosis requires cell-autonomous mesenchymal fibroblast growth factor (FGF) signaling. J. Biol. Chem. 2017;292:10364-10378.

    Not in our library10.1074/jbc.m117.791764

  123. 123.

    Suzuki T., Yasuda H., Funaishi K., Arai D., Ishioka K., Ohgino K., Tani T., Hamamoto J., Ohashi A., Naoki K., et al. Multiple roles of extracellular fibroblast growth factors in lung cancer cells. Int. J. Oncol. 2015;46:423-429.

    Not in our library10.3892/ijo.2014.2718

  124. 124.

    Allen J.T., Knight R.A., Bloor C.A., Spiteri M.A. Enhanced insulin-like growth factor binding protein-related protein 2 (Connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am. J. Respir. Cell Mol. Biol. 1999;21:693-700.

    Not in our library10.1165/ajrcmb.21.6.3719

  125. 125.

    Chang C.C., Shih J.Y., Jeng Y.M., Su J.L., Lin B.Z., Chen S.T., Chau Y.P., Yang P.C., Kuo M.L. Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. J. Natl. Cancer Inst. 2004;96:364-375.

    Not in our library10.1093/jnci/djh059

  126. 126.

    Chien W., Yin D., Gui D., Mori A., Frank J.M., Said J., Kusuanco D., Marchevsky A., McKenna R., Koeffler H.P. Suppression of cell proliferation and signaling transduction by connective tissue growth factor in non-small cell lung cancer cells. Mol. Cancer Res. MCR. 2006;4:591-598.

    Not in our library10.1158/1541-7786.mcr-06-0029

  127. 127.

    Allen J.T., Spiteri M.A. Growth factors in idiopathic pulmonary fibrosis: Relative roles. Respir. Res. 2002;3:13.

    Not in our library10.1186/rr162

  128. 128.

    Kelly K., Kane M.A., Bunn P.A. Growth factors in lung cancer: Possible etiologic role and clinical target. Med. Pediatr. Oncol. 1991;19:450-458.

    Not in our library10.1002/mpo.2950190602

  129. 129.

    Hodkinson P.S., Mackinnon A., Sethi T. Targeting growth factors in lung cancer. Chest. 2008;133:1209-1216.

    Not in our library10.1378/chest.07-2680

  130. 130.

    Funke M., Zhao Z., Xu Y., Chun J., Tager A.M. The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury. Am. J. Respir. Cell Mol. Biol. 2012;46:355-364.

    Not in our library10.1165/rcmb.2010-0155oc

  131. 131.

    Tager A.M., LaCamera P., Shea B.S., Campanella G.S., Selman M., Zhao Z., Polosukhin V., Wain J., Karimi-Shah B.A., Kim N.D., et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat. Med. 2008;14:45-54.

    Not in our library10.1038/nm1685

  132. 132.

    Magkrioti C., Oikonomou N., Kaffe E., Mouratis M.A., Xylourgidis N., Barbayianni I., Megadoukas P., Harokopos V., Valavanis C., Chun J., et al. The Autotaxin-Lysophosphatidic Acid Axis Promotes Lung Carcinogenesis. Cancer Res. 2018;78:3634-3644.

    Not in our library10.1158/0008-5472.can-17-3797

  133. 133.

    Zhu Z., Homer R.J., Wang Z., Chen Q., Geba G.P., Wang J., Zhang Y., Elias J.A. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Investig. 1999;103:779-788.

    Not in our library10.1172/jci5909

  134. 134.

    Hancock A., Armstrong L., Gama R., Millar A. Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am. J. Respir. Cell Mol. Biol. 1998;18:60-65.

    Not in our library10.1165/ajrcmb.18.1.2627

  135. 135.

    Ingram J.L., Rice A.B., Geisenhoffer K., Madtes D.K., Bonner J.C. IL-13 and IL-1beta promote lung fibroblast growth through coordinated up-regulation of PDGF-AA and PDGF-Ralpha. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2004;18:1132-1134.

    Not in our library10.1096/fj.03-1492fje

  136. 136.

    Kaviratne M., Hesse M., Leusink M., Cheever A.W., Davies S.J., McKerrow J.H., Wakefield L.M., Letterio J.J., Wynn T.A. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J. Immunol. 2004;173:4020-4029.

    Not in our library10.4049/jimmunol.173.6.4020

  137. 137.

    Lee C.G., Kang H.R., Homer R.J., Chupp G., Elias J.A. Transgenic modeling of transforming growth factor-beta(1): Role of apoptosis in fibrosis and alveolar remodeling. Proc. Am. Thorac. Soc. 2006;3:418-423.

    Not in our library10.1513/pats.200602-017aw

  138. 138.

    Huang M., Wang J., Lee P., Sharma S., Mao J.T., Meissner H., Uyemura K., Modlin R., Wollman J., Dubinett S.M. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res. 1995;55:3847-3853.

    Not in our library

  139. 139.

    Pastuszak-Lewandoska D., Domanska-Senderowska D., Antczak A., Kordiak J., Gorski P., Czarnecka K.H., Migdalska-Sek M., Nawrot E., Kiszalkiewicz J.M., Brzezianska-Lasota E. The Expression Levels of IL-4/IL-13/STAT6 Signaling Pathway Genes and SOCS3 Could Help to Differentiate the Histopathological Subtypes of Non-Small Cell Lung Carcinoma. Mol. Diagn. Ther. 2018;22:621-629.

    Not in our library10.1007/s40291-018-0355-7

  140. 140.

    Xie M., Wu X.J., Zhang J.J., He C.S. IL-13 receptor alpha2 is a negative prognostic factor in human lung cancer and stimulates lung cancer growth in mice. Oncotarget. 2015;6:32902-32913.

    Not in our library10.18632/oncotarget.5361

  141. 141.

    Chakraborty S., Chopra P., Ambi S.V., Dastidar S.G., Ray A. Emerging therapeutic interventions for idiopathic pulmonary fibrosis. Expert Opin. Investig. Drugs. 2014;23:893-910.

    Not in our library10.1517/13543784.2014.913569

  142. 142.

    Gu L., Tseng S., Horner R.M., Tam C., Loda M., Rollins B.J. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature. 2000;404:407-411.

    Not in our library10.1038/35006097

  143. 143.

    Zhang X.W., Qin X., Qin C.Y., Yin Y.L., Chen Y., Zhu H.L. Expression of monocyte chemoattractant protein-1 and CC chemokine receptor 2 in non-small cell lung cancer and its significance. Cancer Immunol. Immunother. CII. 2013;62:563-570.

    Not in our library10.1007/s00262-012-1361-y

  144. 144.

    Vancheri C., Failla M., Crimi N., Raghu G. Idiopathic pulmonary fibrosis: A disease with similarities and links to cancer biology. Eur. Respir. J. 2010;35:496-504.

    Not in our library10.1183/09031936.00077309

  145. 145.

    Zhang C., Lan T., Hou J., Li J., Fang R., Yang Z., Zhang M., Liu J., Liu B. NOX4 promotes non-small cell lung cancer cell proliferation and metastasis through positive feedback regulation of PI3K/Akt signaling. Oncotarget. 2014;5:4392-4405.

    Not in our library10.18632/oncotarget.2025

  146. 146.

    Swamy S.M., Rajasekaran N.S., Thannickal V.J. Nuclear Factor-Erythroid-2-Related Factor 2 in Aging and Lung Fibrosis. Am. J. Pathol. 2016;186:1712-1723.

    Not in our library10.1016/j.ajpath.2016.02.022

  147. 147.

    Tong Y.H., Zhang B., Fan Y., Lin N.M. Keap1-Nrf2 pathway: A promising target towards lung cancer prevention and therapeutics. Chronic Dis. Transl. Med. 2015;1:175-186.

    Not in our library10.1016/j.cdtm.2015.09.002

  148. 148.

    Seibold M.A., Wise A.L., Speer M.C., Steele M.P., Brown K.K., Loyd J.E., Fingerlin T.E., Zhang W., Gudmundsson G., Groshong S.D., et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N. Engl. J. Med. 2011;364:1503-1512.

    Not in our library10.1056/nejmoa1013660

  149. 149.

    Yu C.J., Yang P.C., Shun C.T., Lee Y.C., Kuo S.H., Luh K.T. Overexpression of MUC5 genes is associated with early post-operative metastasis in non-small-cell lung cancer. Int. J. Cancer. 1996;69:457-465.

    Not in our library10.1002/(sici)1097-0215(19961220)69:6<457::aid-ijc7>3.0.co;2-3

  150. 150.

    Nagashio R., Ueda J., Ryuge S., Nakashima H., Jiang S.X., Kobayashi M., Yanagita K., Katono K., Satoh Y., Masuda N., et al. Diagnostic and prognostic significances of MUC5B and TTF-1 expressions in resected non-small cell lung cancer. Sci. Rep. 2015;5:8649.

    Not in our library10.1038/srep08649

  151. 151.

    Ballester B., Milara J., Sanz C., González S., Guijarro R., Martínez C., Cortijo J. Role of MUC1 in idiopathic pulmonary fibrosis. Proceedings of the European Respiratory Society Congress.

    Not in our library

  152. 152.

    Ballester B., Milara J., Guijarro R., Morcillo E., Cortijo J. Role of MUC4 in idiopathic pulmonary fibrosis. Proceedings of the European Respiratory Society Congress.

    Not in our library

  153. 153.

    Ballester B., Roger I., Contreras S., Montero P., Milara J. Role of MUC1 in idiopathic pulmonary fibrosis: Mechanistic insights. Proceedings of the European Respiratory Society Congress.

    Not in our library

  154. 154.

    Ishikawa N., Hattori N., Yokoyama A., Kohno N. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases. Respir. Investig. 2012;50:3-13.

    Not in our library10.1016/j.resinv.2012.02.001

  155. 155.

    Bafna S., Kaur S., Batra S.K. Membrane-bound mucins: The mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene. 2010;29:2893-2904.

    Not in our library10.1038/onc.2010.87

  156. 156.

    Stroopinsky D., Rajabi H., Nahas M., Rosenblatt J., Rahimian M., Pyzer A., Tagde A., Kharbanda A., Jain S., Kufe T., et al. MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism. J. Cell. Mol. Med. 2018.

    Not in our library10.1111/jcmm.13662

  157. 157.

    Taylor-Papadimitriou J., Burchell J.M., Graham R., Beatson R. Latest developments in MUC1 immunotherapy. Biochem. Soc. Trans. 2018;46:659-668.

    Not in our library10.1042/bst20170400

  158. 158.

    Lederer D.J., Martinez F.J. Idiopathic Pulmonary Fibrosis. N. Engl. J. Med. 2018;378:1811-1823.

    Not in our library10.1056/nejmra1705751

  159. 159.

    Mackinnon A.C., Gibbons M.A., Farnworth S.L., Leffler H., Nilsson U.J., Delaine T., Simpson A.J., Forbes S.J., Hirani N., Gauldie J., et al. Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3. Am. J. Respir. Crit. Care Med. 2012;185:537-546.

    Not in our library10.1164/rccm.201106-0965oc

  160. 160.

    Ramasamy S., Duraisamy S., Barbashov S., Kawano T., Kharbanda S., Kufe D. The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol. Cell. 2007;27:992-1004.

    Not in our library10.1016/j.molcel.2007.07.031

  161. 161.

    Farhad M., Rolig A.S., Redmond W.L. The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment. Oncoimmunology. 2018;7:e1434467.

    Not in our library10.1080/2162402x.2018.1434467

  162. 162.
    Idiopathic Pulmonary Fibrosis: Aberrant Recapitulation of Developmental Programs? · 2008
    No notice
  163. 163.

    Chilosi M., Poletti V., Zamo A., Lestani M., Montagna L., Piccoli P., Pedron S., Bertaso M., Scarpa A., Murer B., et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am. J. Pathol. 2003;162:1495-1502.

    Not in our library10.1016/s0002-9440(10)64282-4

  164. 164.

    Stewart D.J. Wnt signaling pathway in non-small cell lung cancer. J. Natl. Cancer Inst. 2014;106:djt356.

    Not in our library10.1093/jnci/djt356

  165. 165.

    Coon D.R., Roberts D.J., Loscertales M., Kradin R. Differential epithelial expression of SHH and FOXF1 in usual and nonspecific interstitial pneumonia. Exp. Mol. Pathol. 2006;80:119-123.

    Not in our library10.1016/j.yexmp.2005.12.003

  166. 166.

    Stewart G.A., Hoyne G.F., Ahmad S.A., Jarman E., Wallace W.A., Harrison D.J., Haslett C., Lamb J.R., Howie S.E. Expression of the developmental Sonic hedgehog (Shh) signalling pathway is up-regulated in chronic lung fibrosis and the Shh receptor patched 1 is present in circulating T lymphocytes. J. Pathol. 2003;199:488-495.

    Not in our library10.1002/path.1295

  167. 167.

    Moshai E.F., Wemeau-Stervinou L., Cigna N., Brayer S., Somme J.M., Crestani B., Mailleux A.A. Targeting the hedgehog-glioma-associated oncogene homolog pathway inhibits bleomycin-induced lung fibrosis in mice. Am. J. Respir. Cell Mol. Biol. 2014;51:11-25.

    Not in our library10.1165/rcmb.2013-0154oc

  168. 168.

    Giroux-Leprieur E., Costantini A., Ding V.W., He B. Hedgehog Signaling in Lung Cancer: From Oncogenesis to Cancer Treatment Resistance. Int. J. Mol. Sci. 2018;19:2835.

    Not in our library10.3390/ijms19092835

  169. 169.

    Ye Y.Z., Zhang Z.H., Fan X.Y., Xu X.L., Chen M.L., Chang B.W., Zhang Y.B. Notch3 overexpression associates with poor prognosis in human non-small-cell lung cancer. Med. Oncol. 2013;30:595.

    Not in our library10.1007/s12032-013-0595-7

  170. 170.

    Westhoff B., Colaluca I.N., D’Ario G., Donzelli M., Tosoni D., Volorio S., Pelosi G., Spaggiari L., Mazzarol G., Viale G., et al. Alterations of the Notch pathway in lung cancer. Proc. Natl. Acad. Sci. USA. 2009;106:22293-22298.

    Not in our library10.1073/pnas.0907781106

  171. 171.

    Zou B., Zhou X.L., Lai S.Q., Liu J.C. Notch signaling and non-small cell lung cancer. Oncol. Lett. 2018;15:3415-3421.

    Not in our library10.3892/ol.2018.7738

  172. 172.
    The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis · 2018
    No notice
  173. 173.

    Conte E., Gili E., Fruciano M., Korfei M., Fagone E., Iemmolo M., Lo Furno D., Giuffrida R., Crimi N., Guenther A., et al. PI3K p110gamma overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: In vitro effects of its inhibition. Lab. Investig. A J. Tech. Methods Pathol. 2013;93:566-576.

    Not in our library10.1038/labinvest.2013.6

  174. 174.

    Horowitz J.C., Lee D.Y., Waghray M., Keshamouni V.G., Thomas P.E., Zhang H., Cui Z., Thannickal V.J. Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-beta1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor. J. Biol. Chem. 2004;279:1359-1367.

    Not in our library10.1074/jbc.m306248200

  175. 175.

    Kavanaugh W.M., Klippel A., Escobedo J.A., Williams L.T. Modification of the 85-kilodalton subunit of phosphatidylinositol-3 kinase in platelet-derived growth factor-stimulated cells. Mol. Cell. Biol. 1992;12:3415-3424.

    Not in our library10.1128/mcb.12.8.3415

  176. 176.
    Inhibition of PI3K Prevents the Proliferation and Differentiation of Human Lung Fibroblasts into Myofibroblasts: The Role of Class I P110 Isoforms · 2011
    No notice
  177. 177.

    Fumarola C., Bonelli M.A., Petronini P.G., Alfieri R.R. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer. Biochem. Pharmacol. 2014;90:197-207.

    Not in our library10.1016/j.bcp.2014.05.011

  178. 178.

    Mulugeta S., Nguyen V., Russo S.J., Muniswamy M., Beers M.F. A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation. Am. J. Respir. Cell Mol. Biol. 2005;32:521-530.

    Not in our library10.1165/rcmb.2005-0009oc

  179. 179.

    Lawson W.E., Crossno P.F., Polosukhin V.V., Roldan J., Cheng D.S., Lane K.B., Blackwell T.R., Xu C., Markin C., Ware L.B., et al. Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: Association with altered surfactant protein processing and herpesvirus infection. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008;294:L1119-L1126.

    Not in our library10.1152/ajplung.00382.2007

  180. 180.

    Van Moorsel C.H., Ten Klooster L., van Oosterhout M.F., de Jong P.A., Adams H., Wouter van Es H., Ruven H.J., van der Vis J.J., Grutters J.C. SFTPA2 Mutations in Familial and Sporadic Idiopathic Interstitial Pneumonia. Am. J. Respir. Crit. Care Med. 2015;192:1249-1252.

    Not in our library10.1164/rccm.201504-0675le

  181. 181.

    Armanios M.Y., Chen J.J., Cogan J.D., Alder J.K., Ingersoll R.G., Markin C., Lawson W.E., Xie M., Vulto I., Phillips J.A., et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2007;356:1317-1326.

    Not in our library10.1056/nejmoa066157

  182. 182.

    Tsakiri K.D., Cronkhite J.T., Kuan P.J., Xing C., Raghu G., Weissler J.C., Rosenblatt R.L., Shay J.W., Garcia C.K. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc. Natl. Acad. Sci. USA. 2007;104:7552-7557.

    Not in our library10.1073/pnas.0701009104

  183. 183.

    Stuart B.D., Choi J., Zaidi S., Xing C., Holohan B., Chen R., Choi M., Dharwadkar P., Torres F., Girod C.E., et al. Exome sequencing links mutations in PARN and RTEL1 with familial pulmonary fibrosis and telomere shortening. Nat. Genet. 2015;47:512-517.

    Not in our library10.1038/ng.3278

  184. 184.

    Fingerlin T.E., Murphy E., Zhang W., Peljto A.L., Brown K.K., Steele M.P., Loyd J.E., Cosgrove G.P., Lynch D., Groshong S., et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat. Genet. 2013;45:613-620.

    Not in our library10.1038/ng.2609

  185. 185.

    Petrovski S., Todd J.L., Durheim M.T., Wang Q., Chien J.W., Kelly F.L., Frankel C., Mebane C.M., Ren Z., Bridgers J., et al. An Exome Sequencing Study to Assess the Role of Rare Genetic Variation in Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 2017;196:82-93.

    Not in our library10.1164/rccm.201610-2088oc

  186. 186.

    Noth I., Zhang Y., Ma S.F., Flores C., Barber M., Huang Y., Broderick S.M., Wade M.S., Hysi P., Scuirba J., et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: A genome-wide association study. Lancet Respir. Med. 2013;1:309-317.

    Not in our library10.1016/s2213-2600(13)70045-6

  187. 187.

    Bennett W.P., Colby T.V., Travis W.D., Borkowski A., Jones R.T., Lane D.P., Metcalf R.A., Samet J.M., Takeshima Y., Gu J.R., et al. p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res. 1993;53:4817-4822.

    Not in our library

  188. 188.

    Sozzi G., Miozzo M., Donghi R., Pilotti S., Cariani C.T., Pastorino U., Della Porta G., Pierotti M.A. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res. 1992;52:6079-6082.

    Not in our library

  189. 189.

    Takahashi T., Munakata M., Ohtsuka Y., Nisihara H., Nasuhara Y., Kamachi-Satoh A., Dosaka-Akita H., Homma Y., Kawakami Y. Expression and alteration of ras and p53 proteins in patients with lung carcinoma accompanied by idiopathic pulmonary fibrosis. Cancer. 2002;95:624-633.

    Not in our library10.1002/cncr.10708

  190. 190.

    Kawasaki H., Ogura T., Yokose T., Nagai K., Nishiwaki Y., Esumi H. p53 gene alteration in atypical epithelial lesions and carcinoma in patients with idiopathic pulmonary fibrosis. Hum. Pathol. 2001;32:1043-1049.

    Not in our library10.1053/hupa.2001.28246

  191. 191.

    Sozzi G., Veronese M.L., Negrini M., Baffa R., Cotticelli M.G., Inoue H., Tornielli S., Pilotti S., De Gregorio L., Pastorino U., et al. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell. 1996;85:17-26.

    Not in our library10.1016/s0092-8674(00)81078-8

  192. 192.

    Uematsu K., Yoshimura A., Gemma A., Mochimaru H., Hosoya Y., Kunugi S., Matsuda K., Seike M., Kurimoto F., Takenaka K., et al. Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis. Cancer Res. 2001;61:8527-8533.

    Not in our library

  193. 193.

    Karachaliou N., Mayo C., Costa C., Magri I., Gimenez-Capitan A., Molina-Vila M.A., Rosell R. KRAS mutations in lung cancer. Clin. Lung Cancer. 2013;14:205-214.

    Not in our library10.1016/j.cllc.2012.09.007

  194. 194.

    Masai K., Tsuta K., Motoi N., Shiraishi K., Furuta K., Suzuki S., Asakura K., Nakagawa K., Sakurai H., Watanabe S.I., et al. Clinicopathological, Immunohistochemical, and Genetic Features of Primary Lung Adenocarcinoma Occurring in the Setting of Usual Interstitial Pneumonia Pattern. J. Thorac. Oncol. Off. Publ. Int. Assoc. Stud. Lung Cancer. 2016;11:2141-2149.

    Not in our library10.1016/j.jtho.2016.07.034

  195. 195.

    Hwang J.A., Kim D., Chun S.M., Bae S., Song J.S., Kim M.Y., Koo H.J., Song J.W., Kim W.S., Lee J.C., et al. Genomic profiles of lung cancer associated with idiopathic pulmonary fibrosis. J. Pathol. 2018;244:25-35.

    Not in our library10.1002/path.4978

  196. 196.

    Govindan R., Ding L., Griffith M., Subramanian J., Dees N.D., Kanchi K.L., Maher C.A., Fulton R., Fulton L., Wallis J., et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012;150:1121-1134.

    Not in our library10.1016/j.cell.2012.08.024

  197. 197.

    Clamon G.H., Bossler A.D., Abu Hejleh T., Furqan M. Germline mutations predisposing to non-small cell lung cancer. Fam. Cancer. 2015;14:463-469.

    Not in our library10.1007/s10689-015-9796-x

  198. 198.

    Wang Y., Kuan P.J., Xing C., Cronkhite J.T., Torres F., Rosenblatt R.L., DiMaio J.M., Kinch L.N., Grishin N.V., Garcia C.K. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am. J. Hum. Genet. 2009;84:52-59.

    Not in our library10.1016/j.ajhg.2008.11.010

  199. 199.

    Nathan N., Giraud V., Picard C., Nunes H., Dastot-Le Moal F., Copin B., Galeron L., De Ligniville A., Kuziner N., Reynaud-Gaubert M., et al. Germline SFTPA1 mutation in familial idiopathic interstitial pneumonia and lung cancer. Hum. Mol. Genet. 2016;25:1457-1467.

    Not in our library10.1093/hmg/ddw014

  200. 200.

    Maitra M., Wang Y., Gerard R.D., Mendelson C.R., Garcia C.K. Surfactant protein A2 mutations associated with pulmonary fibrosis lead to protein instability and endoplasmic reticulum stress. J. Biol. Chem. 2010;285:22103-22113.

    Not in our library10.1074/jbc.m110.121467

  201. 201.

    Madsen J., Tornoe I., Nielsen O., Koch C., Steinhilber W., Holmskov U. Expression and localization of lung surfactant protein A in human tissues. Am. J. Respir. Cell Mol. Biol. 2003;29:591-597.

    Not in our library10.1165/rcmb.2002-0274oc

  202. 202.

    Chen Z., Fillmore C.M., Hammerman P.S., Kim C.F., Wong K.K. Non-small-cell lung cancers: A heterogeneous set of diseases. Nat. Rev. Cancer. 2014;14:535-546.

    Not in our library10.1038/nrc3775

  203. 203.

    Kropski J.A., Blackwell T.S., Loyd J.E. The genetic basis of idiopathic pulmonary fibrosis. Eur. Respir. J. 2015;45:1717-1727.

    Not in our library10.1183/09031936.00163814

  204. 204.

    Korthagen N.M., van Moorsel C.H., Barlo N.P., Kazemier K.M., Ruven H.J., Grutters J.C. Association between variations in cell cycle genes and idiopathic pulmonary fibrosis. PLoS ONE. 2012;7:e30442.

    Not in our library10.1371/journal.pone.0030442

  205. 205.

    Landi M.T., Chatterjee N., Yu K., Goldin L.R., Goldstein A.M., Rotunno M., Mirabello L., Jacobs K., Wheeler W., Yeager M., et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am. J. Hum. Genet. 2009;85:679-691.

    Not in our library10.1016/j.ajhg.2009.09.012

  206. 206.

    Ye G., Tan N., Meng C., Li J., Jing L., Yan M., Jin T., Chen F. Genetic variations in TERC and TERT genes are associated with lung cancer risk in a Chinese Han population. Oncotarget. 2017;8:110145-110152.

    Not in our library10.18632/oncotarget.22329

  207. 207.

    McKay J.D., Hung R.J., Han Y., Zong X., Carreras-Torres R., Christiani D.C., Caporaso N.E., Johansson M., Xiao X., Li Y., et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nat. Genet. 2017;49:1126-1132.

    Not in our library10.1038/ng.3892

  208. 208.

    Kang J.U., Koo S.H., Kwon K.C., Park J.W., Kim J.M. Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer. Cancer Genet. Cytogenet. 2008;182:1-11.

    Not in our library10.1016/j.cancergencyto.2007.12.004

  209. 209.

    Wu X., Amos C.I., Zhu Y., Zhao H., Grossman B.H., Shay J.W., Luo S., Hong W.K., Spitz M.R. Telomere dysfunction: A potential cancer predisposition factor. J. Natl. Cancer Inst. 2003;95:1211-1218.

    Not in our library10.1093/jnci/djg011

  210. 210.

    Hackett J.A., Feldser D.M., Greider C.W. Telomere dysfunction increases mutation rate and genomic instability. Cell. 2001;106:275-286.

    Not in our library10.1016/s0092-8674(01)00457-3

  211. 211.

    Mora A.L., Rojas M., Pardo A., Selman M. Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease. Nat. Rev. Drug Discov. 2017;16:810.

    Not in our library10.1038/nrd.2017.225

  212. 212.

    Peljto A.L., Zhang Y., Fingerlin T.E., Ma S.F., Garcia J.G., Richards T.J., Silveira L.J., Lindell K.O., Steele M.P., Loyd J.E., et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA. 2013;309:2232-2239.

    Not in our library10.1001/jama.2013.5827

  213. 213.

    Yang J., Xu T., Gomez D.R., Jeter M., Levy L.B., Song Y., Hahn S., Liao Z., Yuan X. The Pulmonary Fibrosis Associated MUC5B Promoter Polymorphism Is Prognostic of the Overall Survival in Patients with Non-Small Cell Lung Cancer (NSCLC) Receiving Definitive Radiotherapy. Transl. Oncol. 2017;10:197-202.

    Not in our library10.1016/j.tranon.2016.12.009

  214. 214.
    Global Methylation Patterns in Idiopathic Pulmonary Fibrosis · 2012
    No notice
  215. 215.

    Takenaka K., Gemma A., Yoshimura A., Hosoya Y., Nara M., Hosomi Y., Okano T., Kunugi S., Koizumi K., Fukuda Y., et al. Reduced transcription of the Smad4 gene during pulmonary carcinogenesis in idiopathic pulmonary fibrosis. Mol. Med. Rep. 2009;2:73-80.

    Not in our library10.3892/mmr_00000064

  216. 216.

    Schutte M., Hruban R.H., Hedrick L., Cho K.R., Nadasdy G.M., Weinstein C.L., Bova G.S., Isaacs W.B., Cairns P., Nawroz H., et al. DPC4 gene in various tumor types. Cancer Res. 1996;56:2527-2530.

    Not in our library

  217. 217.

    Sanders Y.Y., Pardo A., Selman M., Nuovo G.J., Tollefsbol T.O., Siegal G.P., Hagood J.S. Thy-1 promoter hypermethylation: A novel epigenetic pathogenic mechanism in pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 2008;39:610-618.

    Not in our library10.1165/rcmb.2007-0322oc

  218. 218.

    Lung H.L., Bangarusamy D.K., Xie D., Cheung A.K., Cheng Y., Kumaran M.K., Miller L., Liu E.T., Guan X.Y., Sham J.S., et al. THY1 is a candidate tumour suppressor gene with decreased expression in metastatic nasopharyngeal carcinoma. Oncogene. 2005;24:6525-6532.

    Not in our library10.1038/sj.onc.1208812

  219. 219.

    Langevin S.M., Kratzke R.A., Kelsey K.T. Epigenetics of lung cancer. Transl. Res. J. Lab. Clin. Med. 2015;165:74-90.

    Not in our library10.1016/j.trsl.2014.03.001

  220. 220.

    Huang S.K., Scruggs A.M., McEachin R.C., White E.S., Peters-Golden M. Lung fibroblasts from patients with idiopathic pulmonary fibrosis exhibit genome-wide differences in DNA methylation compared to fibroblasts from nonfibrotic lung. PLoS ONE. 2014;9:e107055.

    Not in our library10.1371/journal.pone.0107055

  221. 221.

    Yang M., Shen H., Qiu C., Ni Y., Wang L., Dong W., Liao Y., Du J. High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur. J. Cancer. 2013;49:604-615.

    Not in our library10.1016/j.ejca.2012.09.031

  222. 222.

    Kolenda T., Przybyla W., Teresiak A., Mackiewicz A., Lamperska K.M. The mystery of let-7d—A small RNA with great power. Contemp. Oncol. 2014;18:293-301.

    Not in our library10.5114/wo.2014.44467

  223. 223.

    Nguyen-Ngoc T., Bouchaab H., Adjei A.A., Peters S. BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer. J. Thorac. Oncol. Off. Publ. Int. Assoc. Stud. Lung Cancer. 2015;10:1396-1403.

    Not in our library10.1097/jto.0000000000000644

  224. 224.

    Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G., Anstrom K.J., King T.E., Lasky J.A., Martinez F.J. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N. Engl. J. Med. 2012;366:1968-1977.

    Not in our library10.1056/nejmoa1113354

  225. 225.

    Idiopathic Pulmonary Fibrosis Clinical Research Network, Martinez F.J., de Andrade J.A., Anstrom K.J., King T.E., Raghu G. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014;370:2093-2101.

    Not in our library10.1056/nejmoa1401739

  226. 226.

    Oldham J.M., Ma S.F., Martinez F.J., Anstrom K.J., Raghu G., Schwartz D.A., Valenzi E., Witt L., Lee C., Vij R., et al. TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med. 2015;192:1475-1482.

    Not in our library10.1164/rccm.201505-1010oc

  227. 227.

    Sablina A.A., Budanov A.V., Ilyinskaya G.V., Agapova L.S., Kravchenko J.E., Chumakov P.M. The antioxidant function of the p53 tumor suppressor. Nat. Med. 2005;11:1306-1313.

    Not in our library10.1038/nm1320

  228. 228.

    Vafa O., Wade M., Kern S., Beeche M., Pandita T.K., Hampton G.M., Wahl G.M. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: A mechanism for oncogene-induced genetic instability. Mol. Cell. 2002;9:1031-1044.

    Not in our library10.1016/s1097-2765(02)00520-8

  229. 229.

    Sayin V.I., Ibrahim M.X., Larsson E., Nilsson J.A., Lindahl P., Bergo M.O. Antioxidants accelerate lung cancer progression in mice. Sci. Transl. Med. 2014;6.

    Not in our library10.1126/scitranslmed.3007653

  230. 230.

    Mitani Y., Sato K., Muramoto Y., Karakawa T., Kitamado M., Iwanaga T., Nabeshima T., Maruyama K., Nakagawa K., Ishida K., et al. Superoxide scavenging activity of pirfenidone-iron complex. Biochem. Biophys. Res. Commun. 2008;372:19-23.

    Not in our library10.1016/j.bbrc.2008.04.093

  231. 231.

    Salazar-Montes A., Ruiz-Corro L., Lopez-Reyes A., Castrejon-Gomez E., Armendariz-Borunda J. Potent antioxidant role of pirfenidone in experimental cirrhosis. Eur. J. Pharmacol. 2008;595:69-77.

    Not in our library10.1016/j.ejphar.2008.06.110

  232. 232.

    Behr J., Bendstrup E., Crestani B., Gunther A., Olschewski H., Skold C.M., Wells A., Wuyts W., Koschel D., Kreuter M., et al. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir. Med. 2016;4:445-453.

    Not in our library10.1016/s2213-2600(16)30044-3

  233. 233.
    Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells · 2012
    No notice
  234. 234.

    Lin X., Yu M., Wu K., Yuan H., Zhong H. Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon’s fibroblasts in vitro. Investig. Ophthalmol. Vis. Sci. 2009;50:3763-3770.

    Not in our library10.1167/iovs.08-2815

  235. 235.

    Oku H., Shimizu T., Kawabata T., Nagira M., Hikita I., Ueyama A., Matsushima S., Torii M., Arimura A. Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur. J. Pharmacol. 2008;590:400-408.

    Not in our library10.1016/j.ejphar.2008.06.046

  236. 236.

    Choi K., Lee K., Ryu S.W., Im M., Kook K.H., Choi C. Pirfenidone inhibits transforming growth factor-beta1-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19. Mol. Vis. 2012;18:1010-1020.

    Not in our library

  237. 237.

    Miura Y., Saito T., Tanaka T., Takoi H., Yatagai Y., Inomata M., Nei T., Saito Y., Gemma A., Azuma A. Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone. Respir. Investig. 2018;56:72-79.

    Not in our library10.1016/j.resinv.2017.09.007

  238. 238.

    Xiao H., Zhang G.F., Liao X.P., Li X.J., Zhang J., Lin H., Chen Z., Zhang X. Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease. Int. J. Rheum. Dis. 2018;21:477-486.

    Not in our library10.1111/1756-185x.13247

  239. 239.

    Iwata T., Yoshino I., Yoshida S., Ikeda N., Tsuboi M., Asato Y., Katakami N., Sakamoto K., Yamashita Y., Okami J., et al. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study). Respir. Res. 2016;17:90.

    Not in our library10.1186/s12931-016-0398-4

  240. 240.
    The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts · 2016
    No notice
  241. 241.

    Abdollahi A., Li M., Ping G., Plathow C., Domhan S., Kiessling F., Lee L.B., McMahon G., Grone H.J., Lipson K.E., et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J. Exp. Med. 2005;201:925-935.

    Not in our library10.1084/jem.20041393

  242. 242.

    Aono Y., Nishioka Y., Inayama M., Ugai M., Kishi J., Uehara H., Izumi K., Sone S. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am. J. Respir. Crit. Care Med. 2005;171:1279-1285.

    Not in our library10.1164/rccm.200404-531oc

  243. 243.

    Ishii Y., Fujimoto S., Fukuda T. Gefitinib prevents bleomycin-induced lung fibrosis in mice. Am. J. Respir. Crit. Care Med. 2006;174:550-556.

    Not in our library10.1164/rccm.200509-1534oc

  244. 244.

    Li M., Abdollahi A., Grone H.J., Lipson K.E., Belka C., Huber P.E. Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model. Radiat. Oncol. 2009;4:66.

    Not in our library10.1186/1748-717x-4-66

  245. 245.

    Rhee C.K., Lee S.H., Yoon H.K., Kim S.C., Lee S.Y., Kwon S.S., Kim Y.K., Kim K.H., Kim T.J., Kim J.W. Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice. Respir. Int. Rev. Thorac. Dis. 2011;82:273-287.

    Not in our library10.1159/000327719

  246. 246.

    Adachi K., Mizoguchi K., Kawarada S., Miyoshi A., Suzuki M., Chiba S., Deki T. Effects of erlotinib on lung injury induced by intratracheal administration of bleomycin (BLM) in rats. J. Toxicol. Sci. 2010;35:503-514.

    Not in our library10.2131/jts.35.503

  247. 247.

    Wollin L., Maillet I., Quesniaux V., Holweg A., Ryffel B. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J. Pharmacol. Exp. Ther. 2014;349:209-220.

    Not in our library10.1124/jpet.113.208223

  248. 248.

    Arora A., Scholar E.M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 2005;315:971-979.

    Not in our library10.1124/jpet.105.084145

  249. 249.

    Daniels C.E., Lasky J.A., Limper A.H., Mieras K., Gabor E., Schroeder D.R., Imatinib I.P.F.S.I. Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am. J. Respir. Crit. Care Med. 2010;181:604-610.

    Not in our library10.1164/rccm.200906-0964oc

  250. 250.

    Reck M., Kaiser R., Mellemgaard A., Douillard J.Y., Orlov S., Krzakowski M., von Pawel J., Gottfried M., Bondarenko I., Liao M., et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): A phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15:143-155.

    Not in our library10.1016/s1470-2045(13)70586-2

  251. 251.

    Malouf M.A., Hopkins P., Snell G., Glanville A.R., Everolimus in I.P.F.S.I. An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis. Respirology. 2011;16:776-783.

    Not in our library10.1111/j.1440-1843.2011.01955.x

  252. 252.

    Soria J.C., Shepherd F.A., Douillard J.Y., Wolf J., Giaccone G., Crino L., Cappuzzo F., Sharma S., Gross S.H., Dimitrijevic S., et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2009;20:1674-1681.

    Not in our library10.1093/annonc/mdp060

  253. 253.

    An J., Xue Y., Long M., Zhang G., Zhang J., Su H. Targeting CCR2 with its antagonist suppresses viability, motility and invasion by downregulating MMP-9 expression in non-small cell lung cancer cells. Oncotarget. 2017;8:39230-39240.

    Not in our library10.18632/oncotarget.16837

  254. 254.

    Chung L.Y., Tang S.J., Wu Y.C., Sun G.H., Liu H.Y., Sun K.H. Galectin-3 augments tumor initiating property and tumorigenicity of lung cancer through interaction with beta-catenin. Oncotarget. 2015;6:4936-4952.

    Not in our library10.18632/oncotarget.3210

  255. 255.

    Bai X.Y., Zhang X.C., Yang S.Q., An S.J., Chen Z.H., Su J., Xie Z., Gou L.Y., Wu Y.L. Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines. PLoS ONE. 2016;11:e0149370.

    Not in our library10.1371/journal.pone.0149370

  256. 256.

    Ide M., Tanaka K., Sunami S., Asoh T., Maeyama T., Tsuruta N., Nakanishi Y., Okamoto I. Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. Thorac. Cancer. 2018;9:1519-1521.

    Not in our library10.1111/1759-7714.12853

  257. 257.

    Ueda T., Aokage K., Nishikawa H., Neri S., Nakamura H., Sugano M., Tane K., Miyoshi T., Kojima M., Fujii S., et al. Immunosuppressive tumor microenvironment of usual interstitial pneumonia-associated squamous cell carcinoma of the lung. J. Cancer Res. Clin. Oncol. 2018;144:835-844.

    Not in our library10.1007/s00432-018-2602-z

  258. 258.

    Chen X., Shi C., Meng X., Zhang K., Li X., Wang C., Xiang Z., Hu K., Han X. Inhibition of Wnt/beta-catenin signaling suppresses bleomycin-induced pulmonary fibrosis by attenuating the expression of TGF-beta1 and FGF-2. Exp. Mol. Pathol. 2016;101:22-30.

    Not in our library10.1016/j.yexmp.2016.04.003

  259. 259.

    Cao H., Wang C., Chen X., Hou J., Xiang Z., Shen Y., Han X. Inhibition of Wnt/beta-catenin signaling suppresses myofibroblast differentiation of lung resident mesenchymal stem cells and pulmonary fibrosis. Sci. Rep. 2018;8:13644.

    Not in our library10.1038/s41598-018-28968-9

  260. 260.

    Butts C., Socinski M.A., Mitchell P.L., Thatcher N., Havel L., Krzakowski M., Nawrocki S., Ciuleanu T.E., Bosquee L., Trigo J.M., et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): A randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15:59-68.

    Not in our library10.1016/s1470-2045(13)70510-2

  261. 261.

    Liu Y., Huang G., Mo B., Wang C. Artesunate ameliorates lung fibrosis via inhibiting the Notch signaling pathway. Exp. Ther. Med. 2017;14:561-566.

    Not in our library10.3892/etm.2017.4573

  262. 262.

    Xu L., Yang D., Zhu S., Gu J., Ding F., Bian W., Rong Z., Shen C. Bleomycin-induced pulmonary fibrosis is attenuated by an antibody against KL-6. Exp. Lung Res. 2013;39:241-248.

    Not in our library10.3109/01902148.2013.798056

Cited by papers we hold 4

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.